Method for identifying metastatic sequences

ABSTRACT

The invention relates to methods for the identification of metastatic sequences. Cells from a cell line or an animal tissue are treated to form a cell line predisposed to metastasis. Treated cells are implanted in an animal of at a primary site and incubated for a period of time sufficient for the cells to proliferate and develop metastases at secondary sites. Expressed sequences from cells at the primary and secondary sites are amplified by differential display polymerase chain reaction and compared. Differentially expressed sequences are identical identified and can be cloned and sequenced. These sequences can be used as probes in the diagnosis of metastatic disorders, as probes to isolate metastatic sequences and as a therapeutic agent.

REFERENCE TO RELATED APPLICATION

This patent application is a continuation ofThis application is acontinuation of U.S. application Ser. No. 09/469,316, filed Dec. 22,1999, which is a broadening Reissue Application of U.S. Pat. No.5,783,182, issued Jul. 21, 1998. The patent application issuing as U.S.Pat. No. 5,783,182 claims priority on United States provisional patentapplication, serial number 60/006,838, filed Nov. 16, 1995.

More than one reissue application has been filed for the reissue of U.S.Pat. No. 5,783,182. Application Ser. No. 09/469,316, filed, nowabandoned, is a reissue application of U.S. Pat. No. 5,783,182.Application Ser. No. 09/977,371, filed Oct. 16, 2001, is a continuationof Ser. No. 09/469,316 and a reissue of U.S. Pat. No. 5,783,182.Application Ser. No. 09/985,799, filed Nov. 16, 2001, is a continuationof Ser. No. 09/977,371 and a reissue of U.S. Pat. No. 5,783,182.

RIGHTS IN THE INVENTION

This invention was made in part with United States Government supportunder grant number CA350129, awarded by the National Cancer Institute,National Institute of Health and the United States Government hascertain rights in the invention.

BACKGROUND

1. Field of the Invention

The present invention relates to methods for the identification andisolation of metastatic sequences, to diagnostic probes and kits whichcontain metastatic sequences and to therapeutic treatments forneoplastic disorders based on metastatic sequences.

2. Description of the Background

The development of higher organisms is characterized by an exquisitepattern of temporal and spatially regulated cell division. Disruptionsin the normal physiology of cell division are almost invariablydetrimental. One such type of disruption is cancer, a disease that canarise from a series of genetic events.

Cancer cells are defined by two heritable properties, uncontrolledgrowth and uncontrolled invasion of normal tissue. A cancerous cell candivide in defiance of the normal growth constraints in a cell leading toa localized growth or tumor. In addition, some cancer cells also gainthe ability to migrate away from their initial site and invade otherhealthy tissues in a patient. It is the combination of these twofeatures that make a cancer cell especially dangerous.

An isolated abnormal cell population that grows uncontrollably will giverise to a tumor or neoplasm. As long as the neoplasm remains in a singlelocation, it is said to be benign, and a complete cure may be expectedby removing the mass surgically. A tumor or neoplasm is counted as acancer if it is malignant, that is, if its cells have the ability toinvade surrounding tissue. True malignancy begins when the cells crossthe basal lamina and begin to invade the underlying connective tissue.Malignancy occurs when the cells gain the ability to detach from themain tumor mass, enter the bloodstream or lymphatic vessels, and formsecondary tumors or metastases at other sites in the body. The morewidely a tumor metastasizes, the harder it is to eradicate and treat.

As determined from epidermiological and clinical studies, most cancersdevelop in slow stages from mildly benign into malignant neoplasms.Malignant cancer usually begins as a benign localized cell populationwith abnormal growth characteristic called a dysplasia. The abnormalcells acquire abnormal growth characteristics resulting in a neoplasiacharacterized as a cell population of localized growth and swelling. Ifuntreated, the neoplasia in situ may progress into a malignantneoplasia. Several years, or tens of years may elapse from the firstsign of dysplasia to the onset of full blown malignant cancer. Thischaracteristic process is observed in a number of cancers. Prostatecancer provides one of the more clear examples of the progression ofnormal tissue to benign neoplasm to malignant neoplasm.

The walnut-sized prostate is an encapsulated organ of the mammalian maleurogenital system. Located at the base of the bladder, the prostate ispartitioned into zones referred to as the central, peripheral andtransitional zones, all of which surround the urethra. Histologically,the prostate is a highly microvascularized gland comprising fairly largeglandular spaces lined with epithelium which, along with the seminalvesicles, supply the majority of fluid to the male ejaculate. As anendocrine-dependent organ, the prostate responds to both the major malehormone, testosterone, and the major female hormones, estrogen andprogesterone. Testicular androgen is considered important for prostategrowth and development because, in both humans and other animals,castration leads to prostate atrophy and, in most cases, an absence ofany incidence of prostatic carcinoma.

The major neoplastic disorders of the prostate are benign enlargement ofthe prostate, also called benign prostatic hyperplasia (BPH), andprostatic carcinoma; a type of neoplasia. BPH is very common in men overthe age of 50. It is characterized by the presence of a number of largedistinct nodules in the periurethral area of the prostate. Althoughbenign and not malignant, these nodules can produce obstruction of theurethra causing nocturia, hesitancy to void, and difficulty in startingand stopping a urine stream upon voiding the bladder. Left untreated, apercentage of these prostate hyperplasia and neoplasias may develop intomalignant prostate carcinoma.

In its more aggressive form, transformed prostatic tissues escape fromthe prostate capsule and metastasize invading locally and throughout thebloodstream and lymphatic system. Metastasis, defined as tumor implantswhich are discontinuous with the primary tumor, can occur through directseeding, lymphatic spread and hematogenous spread. All three routes havebeen found to occur with prostatic carcinoma. Local invasions typicallyinvolve the seminal vesicles, the base of the urinary bladder, and theurethra. Direct seeding occurs when a malignant neoplasm penetrates anatural open field such as the peritoneal, pleural or pericardialcavities. Cells seed along the surfaces of various organs and tissueswithin the cavity or can simply fill the cavity spaces. Hematogenousspread is typical of sarcomas and carcinomas. Hematogenous spread ofprostatic carcinoma occurs primarily to the bones, but can includemassive visceral invasion as well. It has been estimated that about 60%of newly diagnosed prostate cancer patients will have metastases at thetime of initial diagnosis.

Surgery or radiotherapy is the treatment of choice for early prostaticneoplasia. Surgery involves complete removal of the entire prostate(radical prostatectomy), and often removal of the surrounding lymphnodes, lymphadenectomy. Radiotherapy, occasionally used as adjuvanttherapy, may be either external or interstitial using ¹²⁵I. Endocrinetherapy is the treatment of choice for more advanced forms. The aim ofthis therapy is to deprive the prostate cells, and presumably thetransformed prostate cells as well, of testosterone. This isaccomplished by orchiectomy (castration) or administration of estrogensor synthetic hormones which are agonists of luteinizinghormone-releasing hormone. These cellular messengers directly inhibittesticular and organ synthesis and suppress luteinizing hormonesecretion which in turn leads to reduced testosterone secretion by thetestes. Despite the advances made in achieving a pharmacologicorchiectomy, the survival rates for those with late stage carcinomas arerather bleak.

SUMMARY OF THE INVENTION

The present invention overcomes the problems and disadvantagesassociated with current strategies and designs and provides new methodsfor the identification of sequences related to metastasis.

One embodiment of the invention is directed to methods for theidentification of a metastatic sequence. One or more oncogenic sequencesare transfected into a cell to form a transfected cell. The transfectedcell is introduced into a primary site of a host animal to establish acolony which is incubated in the animal for a period of time sufficientto develop both a primary tumor and a metastatic tumor. Expressedsequences are harvested from the primary tumor and the metastasis.Harvested sequences are compared to each other and to non-metastaticcells to identify sequences related to metastasis. Dominant metastaticgenes are genes whose expression leads to metastasis. Such genes aretypically expressed at high levels in metastatic cells and notsignificantly expressed in normal or nonmetastatic cells. Recessivemetastatic genes, genes whose expression prevents metastasis, may beselectively expressed in normal and nonmetastatic cells and absent inmetastatic cells. Dominant and recessive metastatic genes may actdirectly or act pleiotropically by enhancing or inhibiting theexpression or function of other dominant and recessive metastatic genes.

Another embodiment of the invention is directed to methods foridentifying metastatic sequences. A mammalian cell is treated with ametastatic agent and the treated cell is implanted into a primary siteof a host mammal. The host animal is maintained for a period of timesufficient for the cells to proliferate and to develop a metastatsismetastasis at a secondary cite site. Expressed squences from cells ofthe primary cite and cells of the secondary site are reverse transcribedinto cDNA by differential display polymerase chain reaction to identifydifferentially expressed sequences.

Another embodiment of the invention is directed to sequences isolated bythe methods of the invention. Sequences may be in the form of DNA, RNAor PNA. The nucleic acid may be single-stranded or double-stranded.Single stranded nucleic acid may be in the form of a sense strand or anantisense strand. In addition, the sequence may be part of a homologousrecombination vector designed to recombine with another metastaticsequence.

Another embodiment of the invention is directed to a method for treatinga neoplastic disorder comprising administering a pharmaceuticallyeffective amount of a metastatic nucleic acid to a patient. The nucleicacid may be single-stranded in the sense or the antisense direction.Alternatively, the nucleic acid may be packaged in a viral vector suchas, for example, a retroviral, a vaccinia or an adenoviral vector.Administration may be performed by injection, pulmonary absorption,topical application or delayed release of the nucleic acid along with apharmaceutically acceptable carrier such as water, alcohols, salts,oils, fatty acids, saccharides, polysaccharides and combinationsthereof.

Another embodiment of the invention is directed to a kit for detectingof the presence or absence of a metastatic sequence.

Other objects and advantages of the invention are set forth in part inthe description which follows, and in part, will be obvious from thisdescription, or may be learned from the practice of the invention.

DESCRIPTION OF THE DRAWINGS

FIG. 1 Schematic showing two paths in the multistep progression tocancer.

FIG. 2 A-B Staining of primary tumor (A) and metastatic deposit (B) fromthe lung of the same animal

FIG. 3 A-D Staining of normal human prostate (A), moderatelydifferentiated human prostate tumor (B and C), and poorly differentiatedprostate tumor (D).

FIG. 4 Schematic of method for isolating a metastatic gene from a geneablated mouse strain.

FIG. 5 A-B Schematic showing method to establish a tumor and ametastatic transplant from fetal tissue(A) and from cell lines andtumors (b).

FIG. 6 Isolation and characterization of nmb gene expression by DD-PCRand RNA blot in primary and metastatic cells.

FIG. 7 Differential expression of multiple genes is determined by DD-PCRand RNA blot of primary and metastatic cells.

FIG. 8 Caveolin identified as a differentially expressed gene by DD-PCR.

FIG. 9 Differential expression of genes isolated by DD-PCR confirmed byRNA blots.

FIG. 10 RNA blot analysis of total tumor mRNA using clone 29 GADPHprobes.

FIG. 11 RNA blot of three independent MPR metastatic tumors and 5 MPRnon-metastatic tumors.

FIG. A-RR 12 Nucleotide sequences of metastatic nucleic acids.

FIG. 13 A-D Characterization of metastatic sequences isolated.

FIG. 14 Immunohistological staining of primary and metastatic humanprostate tumors using anti-caveolin antibodies.

DESCRIPTION OF THE INVENTION

As embodied and broadly described herein, the present invention isdirected to methods for identifying metastatic sequences, to themetastatic sequences identified, to methods for the detection, diagnosisand treatment of disorders related to metastasis, and to diagnostic kitswhich comprise these sequences.

The ability of cancers to metastasize makes tumors difficult toeradicate by any means. Malignant cancer involves a multistageprogression from, for example, normal tissue through hyperplasia, earlyadenoma, early carcinoma and finally to a metastatic tumor (FIG. 1).Cells of a typical tumor loosen their adhesion to their originalcellular neighbors and cross the basal lamina and endothelial lining toenter the body's circulation. Once in circulation, the metastatic cellexits from the circulation to disseminate throughout the body andproliferate in a new environment.

Like the initial oncogenic event, the ability of a cell to metastasizerequires additional mutationic or epigenetic changes. An understandingof the molecular mechanisms of metastasis allow for the design oftreatments to inhibit metastasis. Knowledge of stage specific geneexpression for neoplastic disorders allows for early detection andtyping of tumors. With early detection and typing, proper treatment maybe administered to a patient with the neoplastic disorder earlier, whichwill lead to a higher probability of a complete cure.

For human prostate tumors, the study of stage specific tumors isdifficult, if not impossible, as cell lines are extremely difficult togrow and it is rare that tissue becomes available from the primary tumoras well as metastatic disease from the same patient. This problem isexacerbated because of the infrequent biopsy of metastatic deposits inconjuntion with isolation of material from the primary tumor.Furthermore, the growth of cell lines from malignant prostates hasproved to be problematic over the last few decades. This is evidenced bythe lack of cell lines from prostate cancer obtained under anyconditions.

One embodiment of the invention is directed to a method for identifyinga metastatic sequence. A mammalian cell is transformed into apre-neoplastic or neoplastic state or phenotype by transfection with oneor more oncogenic sequences. Alternatively, or in addition totransfection, the mammalian cell may be treated with an agent orsubjected to a condition that potentiates the metastatic character ofthe cell or predisposes the cell to metastasis. The transfected ortreated cell is implanted into a host animal at a primary site and grownfor a period of time sufficient to develop a metastasis at a secondarysite. Expressed sequences from cells of the primary site and cells atthe secondary site are amplified by differential display polymerasechain reactions. PCR products from these reactions are compared and themetastatic sequence identified by alteration in the levels or patternsof the resulting products.

Mammalian cells from a wide variety of tissue types and species aresuitable for transfection or treatment including surgically obtained orprimary or immortalized cells and cell lines. Cells may be from humansor primates, mice, rats, sheep, cows, rabbits, horses, pigs or guineapigs or from transgenic or xenogeneic host mammals. Cells may beobtained from adult, juvenile or fetal tissue, and used directly fromthe mammal, from cryogenically preserved samples, or after culturing invitro or in vivo for a period of time. In vitro culturing typicallyinvolves tissue culture conditions (e.g. 37° C.; 5% CO₂) while in vivoculturing may involve successive passage of cells through host animalssuch as, for example, mice or rabbits. Cells passed in vivo may beobtained from sites proximal or distal to the site of implantation. Thetissue type from which the cells are derived or obtained may be anytissue which is susceptible to transfection or other treatmentincluding, for example, urogenital tissues, epithelial cells, hepaticcells, fibroblasts lymphatic tissues, hematopoietic cells, cells of theimmune system, cells of the gastrointestinal system and cells of thenervous system.

Cell types useful for the identification of metastatic sequences relatedto prostate cancer include cells and cell lines of the fetal prostatelineage from normal or transgenic animals, and cells from normal orreconstituted prostate tissue. One method of generating reconstitutedprostate cells is to isolate fetal prostate tissue and microdissect thefetal prostate epithelium away from fetal mesenchyme. Fetal prostateepithelium may be genetically manipulated before reassociation withfetal mesenchyme (FIG. 5A). Genetic manipulation involves treatment ortransfection with a metastatic agent or a nucleic acid sequence thataffects neoplastic or metastatic potential of the cell. Reassociation offetal epithelium and mesenchyme is performed by implanting epithelialtissue within a pocket of mesenchymal tissue. After manipulation, cellsare reimplanted into a mammalian host in a similar manner as othercells, such as reimplantation into or under the renal capsule.

Mammalian cells may be transfected by a variety of techniques, all ofwhich are well-known to those of ordinary skill. Direct methods involvethe introduction of genetic material into the nucleus of a cell byinjection. These techniques include high velocity projectile injection,microinjection, and electroporation. Indirect methods, involving theactive or passive uptake of the genetic information by the cell, includetransduction with recombinant vectors, and chemical or physicaltreatments such as calcium phosphate uptake, lipofection or dextransulfate transfection. Chemical techniques rely on chemical carriers tointroduce nucleic acids into a cell. These methods, for example, utilizeunilamellar phospholipid vesicles (e.g. liposomes) loaded with DNA (orRNA). The approach relies on the fusion of the DNA containing vesicleswith the plasma membrane of the recipient cells. After entry, DNAtraverse the cytoplasm and enter the nucleus. Another lipofectiontechnique uses a synthetic cationic lipid such asN-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA).DOTMA spontaneously associates with nucleic acids and forms unilamellarvesicles upon sonication. Genetic material is incorporated into thesevesicles and subsequently transfected into the cell. Calcium phosphateco-precipitation involves mixing of purified nucleic acid with bufferscontaining phosphate and calcium chloride which results in the formationof a fine precipitate. Presentation of this precipitate to cells resultsin incorporation of the nucleic acid into cellular genome. Otherchemicals, such as DEAE dextran or polybrene, when present in media withnucleic acids, can also cause the transfection of mammalian cells.

Physical methods of transfection rely on electric fields, needles andparticles to enable nucleic acids to traverse the cellular membrane.Electric field mediated DNA transfection, commonly calledelectroporation, is based on the principle that membranes, whensubjected to an electric field, undergo a reversible breakdown resultingin pores large enough to permit the passage of nucleic acids. Inmicro-projectile mediated gene transfer, micro-projectiles ofsubcellular dimensions are coated with nucleic acid and propelled athigh velocity into a cell using a particle gun. The nucleic acid isintroduced into the nucleus directly when the particles impinge upon thenucleus. In microinjection, nucleic acid is injected directly into thenucleus of a cell with a needle. Lasers have also been used to introduceminute holes in cellular membrane to allow introduction of nucleicacids. All these methods may be used for transfection and the selectionof the method will depend on the cell type, the desired transfectionefficiency and the equipment available.

The efficiency of transfection may be monitored and enhanced by theco-transfection of a selectable marker. If a marker is co-transfectedwith a genetic construct, positively transformed cells may be separatedfrom nontransformed cells by chemical selection. The efficiency oftransfection will be increased in most cases because the chemicals willselectively kill non-transfected cells. The number of transfected cellsmay also be monitored by analyzing the degree of chemical resistance ofthe transfected cells. Markers commonly used for selection purposesinclude, for example, nucleic acids encoding dihydrofolate reductase,metallothionein, CAD, adenosine deaminase, adenylate deaminase, UMPsynthetase, IMP 5′-dehydrogenase, xanthine-guaninephosphoribosyltransferase, mutant thymidine kinase, mutant HGPRTase,thymi dylate synthetase, P-glycoprotein 170, ribonucleotide reductase,glutamine synthetase, asparagine synthetase, arginosuccinate synthetase,ornithine decarboxylase, HMG-CoA reductase, N-acetylglucosaminyltransferase, theronyl-tRNA synthetase, sodium or potassium dependentATPase or derivatives or mutants of these nucleic acids. Markers may beused individually or in combination. Chemicals useful for selectioninclude methotrexate, cadmium, PALA, Xyl-A, adenosine,2′-deoxycoformycin, adenine, azaserine, coformycin, 6-azauridine,pyrazofuran, mycophenolic acid, limiting xanthine, hypoxanthine,aminopterin, thymidine, 5-fluorodeoxyuridine, adriamycin, vincristine,colchicine, actinomycin D, puromycin, cytocholasin B, emetine,maytansine, Bakers' antifolate, aphidicolin, methionine sulfoximine,β-aspartyl hydroxamate, albizziin, canavanine,α-difluoromethylornithine, compactin, tunicamycin, borrelidin, ouabain,and derivatives and analogs and combinations of these chemicals. Somechemicals, such as methotrexate, may be used individually while otherchemicals, such as HAT (hypoxanthine, aminopterin and thymidine), needto be used in combination to be effective.

The oncogene transfection efficiency, the fraction of live cellstranfected by an oncogene, may be indirectly enhanced by chemicalselection for a co-transfected marker. An oncogene is a sequence whichcan predispose, or induce the cell into a pre-neoplastic or neoplasticcondition or otherwise enhance the metastatic potential of the cell.Sequences with these properties are referred to as oncogenes and includeabl, ahi, akt, bcl, crk, dsi, erb, ets, evi, fes/fps, fim, fis, fgr,flv, fms, fos, gin, gli, int, jun, kit, mas, lck, met, mil/raf, mis,mlv, mos, myb, myc, neu, onc, pim, raf ras, rel, ros, seq, sis, ski,spi, src, tcl, thy, trk, and yes. Some oncogenes, such as ras, areoncogenic when mutated. Other oncogenes, such as myc, are oncogenic whenoverexpressed or underexpressed. Many oncogenes represent members ofmultigene families or homologs families. Homologs are proteins that havesimilar primary, secondary or tertiary structures. Genes may differ innucleic acid sequence or encoded peptide sequence and still be homologswhen the encoded polypeptides have similar spatial folding. Manyoncogenes can be classified into dominant oncogenes and recessiveoncogenes. One or more dominant oncogenes can confer a neoplastic orpre-neoplastic phenotype to a cell. One or more recessive oncogenes,when silenced, may also confer a neoplastic or preneoplastic phenotype.Gene silencing is performed by transfecting cells with nucleic acidswhich cause genetic ablation or by antisense suppression.

While any oncogene may be used, the preferred oncogenes are those thatare normally associated with metastasis such as a metastasis specificgene. Such genes include for example, TGF-β1, Cyclin D1 p21, p34, mutantp53, lysyl oxidase, caveolin, actin binding protein, ubiquitinactivating enzyme E1, nmb or α-actinin 3. Metastatic-specific genes maybe used individually or in combination with other oncogenes.

The metastatic potential of a cell may be altered, for example, by geneablation with of a sequence specific for a recessive oncogene. Recessiveoncogenes are those genes which encode products which can suppressoncogenesis and metastasis. A gene ablation sequence can be designed tospecifically suppress a recessive oncogene. Ablation may includepre-transcriptional inhibition such as homologous recombination withendogenous recessive oncogenes and post transcriptional inhibition suchas the expression of antisense oncogenes to suppress translation. Geneablation sequences may be targeted towards well known recessiveoncogenes such as, for example, the retinoblastoma gene (Rb) or Bcg Bcl.Other candidates for ablation include metastatic genes previouslyisolated by the invention such as, for example, TGF-β1, cyclin D1, p21,p34, mutant p53, lysyl oxidase, caveolin, actin binding protein,ubiquitin activating enzyme E1, nmb or α-actinin-3. The effects ofablating a recessive oncogene may include oncogenesis and metastases.

Alternatively, or in addition to transfection the mammalian cell may betreated with an agent, either before or after transfection, that altersthe expression of the cell's nucleic acids. Treatment may comprisecontacting the cells with one or more agents which affect the neoplasticpredisposition (e.g. neoplastic agents; phorbol esters), metabolization(e.g. metabolic agents), metastasis (e.g. metastatic agents),differentiation (e.g. differentiation agents; retinoic acid), activationor proliferation (e.g. growth factors) of the cell. Agents which canalter gene expression include chemicals such as benzanthracene (BA),dimethyl benzanthracene (DMBA) or 5-azacytidine. Alternatively,treatment may also comprise altered conditions such as hypoxia whichinvolves subjecting a cell to a reduced oxygen content, exposable toradiation or other stresses to the cell.

Treatment may be in vitro or in vivo and may include for example, director indirect induction or suppression of well known oncogenic sequencesand genes isolated by the invention such as, for example, TGF-β1, CyclinD1, mutant p53, lysyl oxidase, caveolin, actin binding protein,ubiquitin activating enzyme E1, nmb, α actinin 3, and p34. Geneexpression induction includes transfecting expression vectorsencompassing coding regions of the gene. Gene repression comprisesintroducing a gene ablation sequence or a repressor of the gene to thecell.

Cells which have one or more genes ablated may also be used. Forexample, a metastatic suppressor gene may be ablated to preventinhibition to metastases. A useful gene for ablation is a gene capableof affecting the phenotype and behavior of a cell or tumor. For example,with prostate tumors, suitable genes include both well known genes andgenes isolated by the methods of the invention such as for example,TGF-β1, Cyclin D1, p21, p34, mutant p53, lysyl oxidase, caveolin, actinbinding protein, ubiquitin activating enzyme E1, nmb and α actinin 3.Genetic ablation (gene knockout) refers to a process of silencing theexpression of a particular gene in a cell. The silencing process mayinclude, for example, gene targeting or antisense blocking. Genetargeting refers to a process of introducing a nucleic acid constructinto a cell to specifically recombine with a target gene. The nucleicacid construct inactivates the targeted gene. Inactivation may be byintroduction of termination codons into a coding region or introductionof a repression site into a regulatory sequence. Antisense blockingrefers to the incorporation into a cell of expression sequences whichdirects the synthesis of antisense RNA to block expression of a targetgene. Antisense RNA hybridizes to the mRNA of the target gene to inhibitexpression.

The host animal is preferably the same species as the implanted cell. Incases of xenogeneic transplants, the host may be immunocompromisedgenetically or by treatment with drugs such as immunosuppressants. Ahost may be immunocompromised genetically by breeding such as with nudemice or severe combined immunodeficient (SCID) mice. A host may also beimmunocompromised by chemical or irradiation methods. An additionalroute to immunocompromise a host is to use transgenic technology tointroduce an immunosuppressing gene or to introduce a foreign antigengene. An immunosuppressing gene is a gene that affects the efficiency ofthe immune system such as a gene which inhibits the formation of cellsof the B cell or T cell lineage. A foreign antigen gene, when expressed,may cause the host to tolerate the antigens in a xenogeneic transplantand not mount an immune response.

Cells may be implanted into any primary site in a host animal, such as,for example, subcutaneous implantation, intravenous injection, orimplantation into the abdominal cardiac, chest, pulmonary, thoracic orperitoneal cavity. Using techniques known to those of ordinary skill inthe art, cells can be placed on or in nearly any organ or tissue.Reasons for choosing a site include ease of implant, proximity ofsimilar tissue type, immunoprivileged position and ease of inspection.Metastasises migrate from the primary site to one or more secondarysites such as, for example, the lung, kidney, liver, lymph nodes, brain,testis, bone, spleen, ovaries or mammary. Preferred sites include therenal capsule, the testes, the prostate and the ovaries.

To avoid histocompatibility problems, the implant may be placed into ahistocompatible host animal. Such problems are generally avoided if theimplant and host animal are syngeneic. Alternatively, anon-histocompatible host may be used if the host can be madeimmunotolerant. Hosts may also be transgenic or immunocompromisedanimals or genetically matched to the mammalian cells to be introduced.Immunocompromised animals may be derived from established mouse linessuch as nude mice or severe combined immune deficiency (SCID) mice, orby treatments such as radiation, chemical, pharmaceutical or genetictargeting. Sufficiently immunosuppressed animals can be made tolerant toxenogeneic transplants.

After implantation the host animal is maintained under normal conditionsto develop metastases. Alternatively, the host animal may be subjectedto an altered treatment or environmental condition to stimulate orrepress metastasis or induce other cellular functions. In metastasis, asub-population of cells of the implantation site invade and establishone or more secondary colonies in the host animal. The behavior of theimplanted cell will depend on the cell type, the transfected sequenceand the implantation location. Typical secondary sites for metastaticcolonies include lung, kidney, liver, lymph nodes, brain, testis,spleen, bone, ovary, skin and mammary tissue. Metastatic developmenttimes vary from days to weeks even months. Cells with a high metastaticpotential tend to progress to metastasis quickly while cells with a lowmetastatic potential may require very long periods of time that spansignificant portions of the lifespan of the animal.

The host animal may be analyzed for metastatic development weekly, fromone week to 20 weeks to six months, nine months or one year afterimplantation. For animals with longer lifespans such as sheep, theanimal may be inspected yearly from one year on up to ten years formetastatic tumors. Metastases can be detected by examinations such aspalpation, biopsy, imaging, exploratory surgery, CAT scans, autopsy,X-ray and direct observation. In addition, tissue samples may be takensurgically from the host mammal and subjected to histological or otherexamination for the detection of metastases.

Expressed sequences include mRNA, rRNA, hnRNA, DNA, cDNA and any nucleicacid sequence that is expressed in the cell. These sequences may beamplified by in situ techniques or by purification of nucleic acid fromcollected cells. Expressed sequences may be obtained by extractingnucleic acids from cells before implantation, at the primary site or atthe secondary site. Cells collected at these sites may optionally becultured for a time before nucleic acid extraction. The effects oftreatment with gene expression modifying agents or environmentalconditions can be ascertained by collecting cells before and aftertreatment. Treatment may be applied to the cells while the cells are inthe host mammal or after the cells are excised and in culture. Nucleicacid are collected from cells using techniques that are well known tothose of ordinary skill in the art.

Expressed sequences may be used directly for polymerase chain reaction(PCR) analysis using, for example, the technique of reversetranscriptase polymerase chain reaction (RT-PCR). Alternatively, RNA maybe enriched for mRNA using a poly-A RNA enrichment method. Numerouspoly-A RNA enrichment methods exist and are commercially available.Techniques used for poly-A RNA enrichment include oligo-dT columns,oligo-dT magnetic beads, and oligo-dT cellulose. RNA may be furtherprocessed into cDNA before analysis by reverse transcription usingreverse transcriptase. The cells or the extracted nucleic acid may bepreserved, such as by freezing, and analyzed at a later time.

Differential display polymerase chain reactions (DD-PCR) are performedon the expressed sequences using two variable primers which may containthe same or entirely different sequences or an anchor primer and avariable primer. If an anchor primer is used, one anchor primer and onevariable primer create a single or a single set of reaction products foreach reaction. A complete profile may include 25 or more different PCRreactions per sample wherein each PCR reaction is performed with thesame anchor primer and a different variable primer. DD-PCR may also beperformed using anchor and variable primers which contain the samesequence. Whether a particular reaction is used depends on whether adifference exists between the products of two PCR reactions using thesame primers. When a significant difference exists between theexpression sequences amplified, one pair of PCR reactions may besufficient and informative.

Anchor primers are preferably oligonucleotides with a poly-T sequence atthe 5′-terminas terminals and a dinucleotide selected from the groupconsisting of AA, AG, AC, AT, GA, GG, GC, GT, CA, CG, CC and CT at the3′-terminas terminals. For example, the sequence may be 5′-TTTTTTAA-3′or 5′-TTTTTTAG-3′. The length of the poly-T sequence is typicallybetween about 5 to about 30 bases in length and preferably between about10 to about 20 nucleotides long. The total length of the anchor primercan vary greatly for each experiment but is preferably between about 7to about 32 and more preferably between about 12 and about 22.Differential diagnostic display polymerase chain reaction may also beperformed using an anchor primer of any sequence and a length betweenabout 5 to about 30, preferably between about 5 to about 20 and morepreferably between about 7 to about 12 bases.

The variable primer may comprise a random sequence, or a specificsequence such as, for example, a sequence of SEQ ID NO. 1 to SEQ ID NO.24. Variable primers preferably are oligonucleotides with a lengthbetween about 5 to about 30, preferably between about 5 to about 20, andmore preferably between about 7 to about 12 bases in length.

To enhance detection of the PCR product, the anchor primer or thevariable primer, or both, may comprise a detectable moiety. Examples ofdetectable moieties include radioactive moieties, phosphorescentmoieties, magnetic moieties, luminescent moieties, conjugatable moietiesor other detectable moiety. A plurality of detectable moieties may beused to enhance detection or to simplify data analysis. Other detectablemoieties include conjugatable moieties and molecules which can bindspecifically to other molecules which are themselves detectable.Examples of conjugatable moieties include avidin, streptavidin, biotin,antibody, antigen, cell adhesion molecules and other molecules withsimilar activities. Detectable moieties are preferably labelednucleotides. A nucleotide may be any natural or synthetic nucleotide ornucleotide analog capable of incorporation into an elongation reactionin a polymerase chain reaction. Labeled nucleotides include nucleotidetriphosphates labeled with one or more radioactive atoms such as ³²P,³³P, ³H, ¹⁴C and ³⁵S. Products of DD-PCR reactions are compared todetect the metastatic sequence. Comparisons can be performed betweenexpressed sequences from cells at secondary sites with cells at anystage in the method including untreated mammalian cells, transfected ortreated manmmalian cells, implanted cells or cells obtained from theprimary site in the host animal. DD-PCR products may be analyzed by anymethod which reliably compares the products of two polymerase chainreactions. Typical analytical methods used for this purpose includepolyacrylamide gel electrophoresis, capillary electrophoresis and highpressure liquid chromatography (HPLC). Product produced from DD-PCR maybe analyzed in double-stranded or single-stranded forms. When theproducts of the DD-PCR reaction are labeled the sizes and distributionof the products may be monitored and analyzed by following the labelsusing a radiation monitor or by autoradiography. For example, DD-PCRperformed in the presence of radioactive primers or nucleotidetriphosphates, can be analyzed by gel electrophoresis, by capillaryelectrophoresis, or by HPLC. Products are easily monitored by thepresence of radioactivity.

Another method for analyzing and isolating metastatic sequences is tosequence the amplified nucleic acid sequences. Sequencing may beperformed using standard methods well known to those of ordinary skillin the art. The resulting sequence may be compared to a sequencedatabase created or well-known, such as Genbank, for identification orfor locating homologs. The sequencing information may be used tocalculate the physical characteristics of the nucleic acids such asmelting temperature and secondary structure. The primary sequence andthe physical characteristic may be used to synthesize optimal nucleicacid probes for the detection or staging of metastasis or conditionsthat are predictive of the presence or absence of the metastaticcondition.

Another embodiment of the invention is directed to a method foridentifying a metastatic sequence. A mammalian cell is pretreated with ametastatic agent to form a population of cells predisposed tometastasize. The treated cells are introduced into a host mammal at aprimary site. The host animal is maintained for a period of timesufficient to develop a metastasis at a secondary site. Expressedsequences of cells at the primary site and cells at the secondary siteare treated with a genotoxic agent or subjected to genotoxic conditions.Expressed sequences of the treated cells are amplified by differentialdisplay polymerase chain reaction and compared with untreated cells fromany previous step to identify the metastasis sequence.

The metastatic agent may be a chemical compound, a nucleic acid or aprotein that alters the metastatic potential of a cell or relates to oris associated with the metastatic process. Chemical compounds includeretinoids such as 4-hydroxyphenyl (4HP). Other agents include theproteins TGF-β1, Cyclin D1, p21, p34, mutant p53, lysyl oxidase,caveolin, actin binding protein, ubiquitin activating enzyme E1, nmb orα-actinin 3, or their respective genes. The metastatic agent may be ametastatic stimulant or a metastatic suppressant. Metastatic stimulantsmay be used to enhance the sensitivity of the metastasis sequencedetection method. Conversely metastatic suppressants may be used todecrease the sensitivity of the method enabling the selectiveidentification of potent metastatis metastatic sequences or sequencesspecific to a particular tissue type or detastatic disorder. Treatmentmay comprise direct contact with the metastatic agent or incubation fora period of time. Metastatic agents enhance the metastatic potential ofthe implanted cells and increase the sensitivity and the speed of theoverall method.

The cells at the primary site and the metastatic cells at the secondarysite may be treated with a genotoxic agent in vivo or in vitro. In vivotreatment may comprise injecting genotoxic agents directly into the hostmammal or specifically applying the agent with, for example, topicalformulations. The cells at the primary site and the secondary site mayalso be isolated from the host animal and treated with the genotoxicagent in culture. Genotoxic agents are chemical compounds, nucleic acidsor proteins that alter gene expression by effecting the nucleic acidgenome directly by, for example, chemical modification, or indirectlyby, for example, altering components associated with gene expression.Such agents include, for example, benzanthracene (BA), dimethylbenzanthracene (DMBA) and 5-azacytidine, and may include metastaticagents as well. In addition to or in place of genotoxic agents, thecells may be treated to hypoxic conditions or radiation to alter geneexpression. Metastatic sequences identified in these methods may bespecific for particular genotoxic agents or conditions.

Another embodiment of the invention is directed to the use of a hostanimal with an altered genotypic or phenotypic predisposition formetastases. A host animal may be screened for endogenous expression ofmetastases gene. Examples of metastatic sequences which may be screenedfor include sequences isolated by the method of the invention, such as,for example, the sequences listed in FIG. 12 and FIG. 13. Particularlyuseful metastatic sequences include TGF-.beta.. A host animal withreduced levels of a metastatic gene product may be used to isolate novelmetastatic genes. Host animals may be screened for reduced levels ofmetastatic gene expression. In addition, transgenic technology may beuse to ablate a metastatic gene in the germline of a host animal.

Another embodiment of the invention is directed to analysis of a cellline before their use as a starting material to isolate metastatic genesin a particular pathway. Analysis is useful in identifying cells, andconsequently sequences specific to these cells, which are particularlysusceptible or resistant to metastatic transformation. For example, acell highly predisposed to metastasis may be especially sensitive fordetecting metastatic genes. Conversely, a cell showing high resistanceto metastasis can be used to isolate especially potent metastaticsequences. One method to analyze susceptibility to metastasis is todetermine the cellular response to growth factors or growth inhibitors.Briefly, a control population and a test population of cells are exposedto a growth factor or a growth inhibitor and the cellular response (e.g.proliferation, metabolism) recorded. Cells showing abnormal responses tothe growth factor or growth inhibitor may be used as the startingmaterial for metastatic gene isolation. Cellular response includechanges in the rate of cellular division (e.g. thymidine uptake),changes in the expression of RNA or proteins, changes in cellularlocalization or modification patterns of RNA or proteins, and changes inthe rate of uptake, release or metabolism of nutrients.

Especially potent or weak metastatic genes may be detected by treatingand analyzing the metastatic potential of different cells and selectinga suitable cell type as the starting material. For example, cells may betreated with myc, ras, mutant p53 or combinations thereof and analyzedfor cyclin D1 expression which is shown to correlates correlate withmetastasis. FIG. 2 shows the in situ analysis of cyclin D1 in primaryMPR tumors (FIG. 2A) and in metastatic deposits from the lung of thesame animal (FIG. 2B). The gene expression pattern of cyclin D1 in MPRcorrelates with that of human prostate tumors (FIG. 3) analyzed withstains specific for cyclin D1 expression. Normal human tissue shows nocyclin D1 expression or staining (FIG. 3A). Moderately differentiatedprostate cancers with dispersed (FIG. 3B) or focal positively staining(FIG. 3C) show moderate staining. Advanced poorly differentiatedprostate cancer cells show strong nuclear as well as cytoplasmicstaining (FIG. 3D) implying strong expression of cyclin D1. Aftertreatment with myc, ras or mutant p53, cyclin D1 expression showscorrelation with the metastatic potential of the cell. Thus, cyclin D1expressing cells are a source of cells with high metastatic potential.Conversely, cells with low cyclin D1 expression are a source ofpotentially metastatically metastasis resistant cells.

This method may be adjusted for the isolation of metastatic sequencesexpressed along a particular developmental or differentiation pathway bycombining the various treatment and analytical techniques. This approachis schematically represented in FIG. 4. For example, a mammalian cellmay be genetically ablated for TGF-β6, Cyclin D1, mutant p53, lysyloxidase, caveolin, actin binding protein, ubiquitin activating enzymeE1, nmb, α actinin 3, or p34. The genetically altered cell is used in anin vivo mouse prostate reconstitution (MPR) model. Metastatic andnonmetastatic cells isolated from the MPR may be analyzed directly orafter induction with an agent such as the TGF-β gene or its product.Analysis involves the use of differential display polymerase chainreaction to identify differentially expressed bands. Sequencesidentified may be used for subsequent ablation, transformation ordifferential analysis.

Genetic ablation (gene knockout) may be performed after a cell isselected or by selecting a cell comprising a genotype with the propergenetic ablation. Cells already comprising gene ablation may be acquiredfrom a cell depository, from other laboratories or from a transgenicanimal. As transgenic animals comprise genetically ablated genes inevery cell, any tissue from a transgenic animal may be used as thestarting material.

The effects of oncogenes are at least additive and often synergistic.Thus, dominant oncogenes may be transfected together or multiplerecessive oncogenes ablated together for a stronger effect. Furthermore,both methods may be combined and dominant oncogene transfection may beaccompanied by recessive oncogene ablation.

The function of the metastatic sequence may be determined by thedifferential expression pattern. For example, a dominate dominantmetastatic gene will be present in a metastatic cell while a recessivemetastatic gene is present in a non-metastatic cell. Metastaticsequences may be detected as bands which are present in the DD-PCR ofmetastases isolated in secondary sites and yet absent from DD-PCRproducts of primary cells. These sequences may be dominant metastaticgenes whose expression is directly responsible for metastases, or theymay be metastasis associated genes whose expression correlates withmetastasis. Either are useful for therapy and diagnosis. Conversely,DD-PCR bands which are present in primary site tumors, but absent insecondary metastatic sites, may be dominant metastasis suppressiongenes. Dominant metastasis suppression genes comprise genes whoseexpression suppresses metastasis while nonmetastatic genes comprisegenes whose expression correlates with non-metastatic tissue. Geneswhich are highly correlative with either the metastatic phenotype or thenon-metastatic phenotype may be isolated. Isolation can be performed bycutting the appropriate nucleic acid in the containing band of from apolyacrylamide gel or by collecting the appropriate fraction in an HPLCor capillary electrophoresis. The nucleic acid may be cloned into aplasmid vector, and sequenced, or synthetically prepared.

Another embodiment of the invention is directed to a method foridentifying sequences in a metastatic pathway which are responsive orunresponsive to extracellular signals. Such sequences may be used intherapy and diagnosis of metastatic disorders. Implanted cells or cellsfrom a primary site and cells from a secondary site are treated withextracellular signals. RNA sequences from the treated cells are comparedwith RNA sequences of the untreated cells (FIG. 5B). Treated cells anduntreated cells may be derived from a short term or long term in vitroculture of primary tumors and malignant tumors. Alternatively, a part ofa primary tumor and a part of a malignant tumor may be collected beforethe animal is treated with an extracellular cytokine or other factor.Long term cultures, or cell lines of primary and malignant cells mayalso be used as recipients of extracellular growth signal treatment.Suitable signals for each experiment will depend on the cell type.Generally, growth factors, lymphokines, inhibitory factors, migratoryfactors or hormones may be used. Factors previously isolated bycommercial or methods of the invention and factors associated with orcausative or suppressive of metastasis are preferred. Thus, transforminggrowth factor β1 (TFG-β1) may be used to treat cells before DD-PCRanalysis. Proteins encoded by the genes isolated by this method areespecially useful for the treatment of cells for the isolation ofadditional sequences. The identification of one sequence responsive tothe extracellular signal pathway allows for identification of additionalgenes upstream and downstream from that sequence.

Another embodiment of the invention is directed to metastatic sequencesidentified by the methods of the invention. Metastatic sequences aresequences associated with the presence or absence of a metastasis orrelated to the metastatic process can be used in the therapeutictreatment of metastasis. Metastatic-related sequences include dominantmetastatic sequences, recessive metastatic sequences, metastasisassociated sequences, dominant oncogenes, recessive oncogenes and cellcycle genes. These genes encode for example, proteins involved in cellcycle, signal processing, DNA replication, growth regulation, inter andintra cellular signaling transcription control and translation control.Isolated sequences are useful in the treatment and for the detection ofmetastatic and other disorders. Disorders which may be treated comprisediseases involving proteins and sequences which are isolated byinteraction with the sequences and proteins isolated by the method ofthe invention. Both malignant or nonmalignant disorders may be treated.Non malignant disorders include hyperplasia, dysplasia and hypertrophy.Examples of nonmalignant disorders include benign enlargement of theprostate, nodular hyperplasia, and benign prostatic hypertrophy.

Treatment may involve gene replacement, gene targeting, antisenseinhibition, gene expression or gene suppression. Gene replacementinvolves replacing a copy of a defective gene with another copy byhomologous recombination. Gene targeting involves the disruption of acellular copy of a gene by homologous recombination. Antisenseinhibition exploits the specificity of hybridization reactions betweentwo complementary nucleic acid chains to suppress gene expression.Cloned genes can be engineered to express RNA from only one or the otherDNA strands. The resultant RNA hybridizes to the sense RNA and inhibitsgene expression. Gene expression and gene suppression involve theintroduction of genes whose expression actively inhibits neoplastictransformation and metastasis.

Another embodiment of the invention is directed to nucleic acids whichcomprise a sequence identified by the methods of the invention. Thenucleic acid may be DNA, RNA or PNA and may be used as a diagnostic toolin the treatment of neoplastic disorders and malignant tumors. Thenucleic acids may comprise additional sequences such as promoters, forexpression of a sense or antisense message, recombination sequences forgene targeting, selectable markers for transfections, or replicationorigins for passage in a prokaryotic or eukaryotic host such as animalcells, bacteria or yeast.

Another embodiment of the invention is directed to nucleic acids whichcomprise sequences identified by the method of the invention such as,for example, the caveolin gene, ABP280 (actin binding protein 280), thelysyl oxidase gene, and the nmb gene (clone 29), and other sequenceslisted in FIG. 12 and FIG. 13. Nucleic acids comprising a sequencecorresponding to these genes may be used in treatment or diagnosis andin diagnostic kits for screening biological samples for the presence orabsence of metastasis or metastatic potential. Treatment may involveusing the sequences in gene therapy, including gene ablation, geneexpression and antisense suppression. Diagnosis may involve genotypicanalysis of samples to determine the existence and expression levels ofthe expressed sequences.

Another embodiment of the invention is directed to the use of caveolingene and protein in the isolation of oncogenes and in the treatment ofneoplastic disorders such as, for example, prostate cancer. Caveolin isan integral membrane protein and a principal component of caveolae.Caveolae are small invaginations at or near the plasma membrane of mostsmooth muscle cells and may function as a component of specific signaltransduction pathways. Surprisingly, caveolin expression increases inmetastatic human prostate cells as compared to human primary prostatetumors.

As caveolin expression correlates with metastasis, application ofbiological technologies designed to block the activity of caveolin orthe function of caveolae may have therapeutic benefits for the treatmentof neoplastic disorders such as human prostate tumors. Specifictreatment approaches using caveolin may include the delivery ofantisense or dominant negative caveolin sequences using expression orviral vectors; as well as the use of specific anti-caveolin antibodies.Additional approaches could also target the cavoeolae, but are notspecifically based on caveolin function. Additional protein andnon-protein components of caveolae could also be targeted for abrogationor the local or systemic administration of nutritional or biologicalagent may also be used. For example, caveolae are extremely rich incholesterol and disruption or depletion of this molecule may alter thefunction of caveolae.

Another embodiment of the invention is directed to methods for treatinga neoplastic disorder comprising administering a pharmaceuticallyeffective amount of composition containing a nucleic acid having asequence identified according to the methods of this invention, itsexpression product or fragments of either. The nucleic acid may be inthe form of a sense or antisense single-stranded or double-strandednucleic acid. The composition may be combined with a pharmaceuticallyacceptable carrier such as water, alcohols, salts, oils, fatty acids,saccharides, polysaccharides administered by injection, pulmonaryabsorption, topical application or delayed release. More than onecarrier may be used together to create a pharmaceutical with desirableproperties.

Another embodiment of the invention is directed to a kit or diagnosticacid aid for screening biological samples for detection of metastasis,or neoplasia or kits . Kits comprise sequences isolated according to themethods of the invention and reagents and materials useful in such kits,such as, for example, buffers, salts, preservatives, and carriers, allof which are well known to those of ordinary skill in the art. Kits areuseful for the analysis of tissues to screen those for the determinationof normal, nonmalignant neoplastic or malignant cells. Kits may compriseadditional reagents useful for the extraction of nucleic acids from atissue sample. Reagents for analyzing the nucleic acid extracted from atissue sample such as polymerase chain reaction reagents and Southernblots reagents may also be included.

The following experiments are offered to illustrate embodiments of theinvention and should not be viewed as limiting the scope of theinvention.

EXAMPLES Example 1

Production of Mouse Prostate Reconstitution Tumors and Metastasis.

Mouse Urogenital Sinus (UGS) tissue was isolated from 17 day old miceembryos. Each isolated UGS was digested with 1% trypsin for three hoursat 4° C. The trypsin was inactivated by the addition of fetal calfserum. UGS cells were digested with 0.125% collagenase for 1.5 hours,counted and mixed at the appropriate cell ratios prior to infection withretrovirus in the presence of polybrene. Retroviruses used includeZipras/myc-9. Control experiments were performed using BAGA virus. Aftera two-hour infection, the infected cells were centrifuged and individualreconstitutions containing 1.5·10⁶ cells produced by resuspending thecells in rat tail collagen at a density of 6.0·10⁷ cells per ml.Aliquots of the infected UGS cells were placed in (DME) with 10% fetalcalf serum overnight at 37° C., 5% CO₂.

The next morning each cell/collagen reconstitution was implanted underthe renal capsule of an adult male +/+ animal. Reconstitutions wereharvested from the mice five weeks later when they showed signs ofobvious distress from the tumor burden. Metastasized tumors wereisolated from the same mice at sites outside the renal capsule. Isolatedtumors and metastasises were either stored in liquid nitrogen or inpreservatives such as 10% buffered formalin.

Cell lines were derived from fresh tumors by mincing a small portion ofthe primary and metastatic tumor and placing each in explant culture inDulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal calfserum. Cells which grow from each explant were propagated in DMEM and10% fetal calf serum.

For histological analysis, a portion of a fresh tumor was fixed in 10%buffered formalin and embedded in paraffin for sectioning and stainingwith hematoxylin and eosin (H&E) or immunohistochemical staining.Immunohistochemical localization of cytokeratins was detected usingpolyclonal cytokeratin antiserum A575 (Dake Co.; Carpinteria, Calif.)and Vectastain ABC kit (Vector Laboratories; Burlingame, CA).

Example 2

Isolation of C-DNA for DD-PCR.

Total cellular RNA was isolated by ultracentrifugation through cesiumchloride. Briefly, up to one gram of cells from culture, tumors ororgans was placed into 4 ml of ice-cold GIT buffer (4M guanidineisothiocyanate, 0.025M sodium acetate, 0.1M M β-mercaptoethanol) andhomogenized in a tissue homogenizer (Polytron or equivalent). Thehomogenate was carefully layered over 4 ml of 5.7M CsCl, 0.024M sodiumacetate (1.8 g CsC1 per ml) in a centrifuge tube. The layers werecentrifuged at 35,000 RPM for 18 hours in a SW50.1 rotor. DNA wascollected from the interface between the cushion and the supernatant,diluted two folds with water, added to 2.5 volumes of ethanol andspooled out on a glass rod. RNA that formed a pellet on the bottom ofthe CsCl layer was resuspended, and once extracted with an equal volumeof phenol:chloroform (1:1), twice with chloroform and precipitated withethanol and resuspended in diethylpyrocarbonate treated water. Theconcentration of DNA and RNA were be determined by absorption at 260nanometers.

Example 3

Differential Display Polymerase Chain Reaction.

mRNA isolated from primary tumors or metastasis was reverse transcribedwith one of the primers and subjected to DD-PCR using the same primer asboth the forward and reverse primer. A set of 24 primers comprisingshort oligonucleotides were used for both the reverse transcription ofmRNA into c-DNA and for differential display polymerase chain reaction.The sequence of the primers used are shown in Table 1.

TABLE 1 Primer No. Sequence Sequence number 1 5′-TGACAATCG-3′ (SEQ. ID.NO. 1) 2 5′-ACTAAGGTC-3′ (SEQ. ID. NO. 2) 3 5′-TCTGCGATCC-3′ (SEQ. ID.NO. 3) 4 5′-ATACCGTTGC-3′ (SEQ. ID. NO. 4) 5 5′-TACGAAGGTC-3′ (SEQ. ID.NO. 5) 6 5′-TGGATTGGTC-3′ (SEQ. ID. NO. 6) 7 5′-CTTTCTACCC-3′ (SEQ. ID.NO. 7) 8 5′-GGAACCAATC-3′ (SEQ. ID. NO. 8) 9 5′-TGGTAAAGGG-3′ (SEQ. ID.NO. 9) 10 5′-TCGGTCATAG-3′ (SEQ. ID. NO. 10) 11 5′-CTGCTTGATG-3′ (SEQ.ID. NO. 11) 12 5′-GATCAAGTCC-3′ (SEQ. ID. NO. 12) 13 5′-GATCCAGTAC-3′(SEQ. ID. NO. 13) 14 5′-GATCACGTAC-3′ (SEQ. ID. NO. 14) 155′-GATCTGACAC-3′ (SEQ. ID. NO. 15) 16 5′-TTAGCACCTC-3′ (SEQ. ID. NO. 16)17 5′-ACCTGCATGC-3′ (SEQ. ID. NO. 17) 18 5′-GCTATACTGC-3′ (SEQ. ID. NO.18) 19 5′-AGTTGCCAGG-3′ (SEQ. ID. NO. 19) 20 5′-AAGCCGTGTC-3′ (SEQ. ID.NO. 20) 21 5′-TCAACGCTCA-3′ (SEQ. ID. NO. 21) 22 5′-TGTTCGAATC-3′ (SEQ.ID. NO. 22) 23 5′-CGAGTCAGAC-3′ (SEQ. ID. NO. 23) 24 5′-TATGAGTCCG-3′(SEQ. ID. NO. 24)

PCR was performed using standard conditions with 40 cycles ofdenaturation at 94° C. for 40 seconds, annealing at 40° C. for 2minutes, and elongation at 72° C. for 35 seconds. After PCR, theproducts were analyzed with non-denaturing polyacrylamide gelelectrophoresis (PAGE) at 12 watts for 15 hours. Bands which differedbetween test and control samples were eluted from the gel, subjected toreamplification by PCR and cloned. Polyacrylamide gel electrophoresis ofDD-PCRs, and the accompanying RNA blot analysis showing the isolation ofsequences with substantial similarity to nmb and TGF-β is shown in FIG.6 and FIG. 7 respectively. Additional sequences isolated by this methodshow substantial similarity to lysyl oxidase, actin binding protein,ubiquitin activating enzyme E1, α-actinin, and P34 ribosomal bindingprotein sequence (FIG. 8). Differential expression of caveolin wasdemonstrated by DD-PCR followed by PAGE (FIG. 9).

Example 4

p53 Allelotype Determination.

The p53 allelotype of a cell sample was determined by PCR. Briefly,nucleic acid is extracted from a tissue sample or a cell culture sample.An aliquot of nucleic acids in placed in 45 μl aliquot of a master mixwhich contained a final concentration of 0.2 mM of each dATP, dTTP,dGTP, dCTP, 1.5 mM MgCl², 0.5 unit Taq polymerase, 0.05 μM of each oftwo primers set specific for the normal wildtype allele of p53(5′-GTGTTTCATTAGTTCCCCACCTTGAC-3′, SEQ. ID NO. 25;5′-AGAGCAAGAATAAGTCAGAAGCCG-3′, SEQ. ID NO. 26). A control set ofprimers specific for the fibroblast growth factor-7 gene was used tomonitor the polymerase chain reaction experiment(5′-ACAGACCGTGCTTCCACCTCGTC-3′, SEQ. ID NO. 27;5′-CCTCATCTCCTGGGTCCCTTTCA-3′, SEQ. ID NO.28). One μl of the reactionfrom the first round of PCR was used as the starting material for asecond round of PCR using a second set of wildtype p53 specific primer(5′-GTCCGCGCCATGGCCATATA-3′, SEQ. ID NO. 29;5′-ATGGGAGGCTGCCAGTCCTAACCC-3′, SEQ. ID NO. 30). This second round ofPCR was also monitored using a control set of primers specific for thefibroblast growth factor-7 (5′-ACAGACCGTGCTTCCACCTCGTC-3′, SEQ. ID NO27; 5′-CCTCATCTCCTGGGTCCCTTTCA-3′, SEQ. ID NO 28).

After PCR the products were analyzed with non-denaturing polyacrylamidegel electrophoresis (PAGE) at 12 watts for 15 hours. Bands whichdiffered between test and control were eluted from the gel, subjected toreamplification by PCR and cloned.

Example 5

Induction of cell lines with TGFβ6 Influence Cellular Gene Expression.

1481-PA cells were grown overnight in DME supplemented with 10% fetalcalf serum overnight at 37° C., and 5% CO₂. Induction was performed bytreatment with TGF-β1 at a concentration of 2 nanograms per ml. Thetreated cells were returned to the incubator and cultured for 12 hours.After induction, cells were washed in phosphate buffered saline andharvested and concentrated by centrifugation.

RNA was extracted from treated and untreated cells and subjected toDD-PCR. Differentially expressed bands detected by DD-PCR were clonedand differential expressions were confirmed using RNA blots (FIG. 10).Subsequent cloning and sequencing identified the bands as ABP280 orfilamin.

One gene isolated showed differential expression in cells induced byTGF-β (FIG. 11, clone 29), while a control probe on the same cell lineshowed no difference in expression levels (FIG. 11, GAPDH).

Example 6

Metastatic Sequences Isolated.

Using the methods of Examples 1, 2, 3, 4, and 5, a plurality ofmetastatic sequences were isolated and sequenced. The expression of themetastatic sequences in primary cells and in metastatic cells weredetermined using RNA blots. The nucleic acid sequences of other isolatedsequences are listed in FIG. 12. Sequence analysis and expressionanalysis was performed on the isolated cloned and the results of thesestudies are summarized in FIG. 13.

Example 7

Caveolin Immunoassay in Human Prostate Cancers.

Primary site human prostate tumors and metastases were isolated andanalyzed for caveolin expression by immunoassay. The results of theassay is shown in Table 3. Metastases shows higher levels of caveolinproteins in metastases than in primary tumors. Immunohistology of tissuesections reveals both elevated levels and distinct distribution ofcaveolin protein in metastatic human prostate when compared to a primaryhuman prostate tumor (FIG. 14).

TABLE 3 Patients Primary-site Metastases in lymph node 1 + ++ 2 ++ +++ 3++ +++ 4 ++ ++ 5 + + 6 ++ ++ 7 ++ +++ 8 + + 9 − − 10 + + 11 + + 12 ++ ++13 + + 14 ++ +++

Other embodiments and uses of the invention will be apparent to thoseskilled in the art from consideration of the specification and practiceof the invention disclosed herein. The specification and examples shouldbe considered exemplary only with the true scope and spirit of theinvention indicated by the following claims.

SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 175(2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 9 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 1: TGACAATCG 9 (2) INFORMATION FOR SEQID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 2: AGCTAAGGTC 10 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:TCTGCGATCC 10 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: ATACCGTTGC 10(2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: TACGAAGGTG 10 (2) INFORMATIONFOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 basepairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE:NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 6: TGGATTGGTC 10 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:CTTTCTACCC 10 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: GGAACCAATC 10(2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: TGGTAAAGGG 10 (2) INFORMATIONFOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 basepairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE:NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 10: TCGGTCATAG 10 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: CTGCTTGATG 10 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: GATCAAGTCC 10(2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: GATCCAGTAC 10 (2) INFORMATIONFOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 basepairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE:NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 14: GATCACGTAC 10 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: GATCTGACAC 10 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: TTAGCACCTC 10(2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: ACCTGCATGC 10 (2) INFORMATIONFOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 basepairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE:NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 18: GCTATACTGC 10 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: AGTTGCCAGG 10 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: AAGCCGTGTC 10(2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: TCAACGCTCA 10 (2) INFORMATIONFOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 basepairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE:NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 22: TGTTCGAATC 10 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: CGAGTCAGAC 10 (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: TATGAGTCCG 10(2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: GTGTTTCATT AGTTCCCCAC CTTGAC26 (2) INFORMATION FOR SEQ ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: AGAGCAAGAA TAAGTCAGAA GCCG 24(2) INFORMATION FOR SEQ ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: ACAGACCGTG CTTCCACCTC GTC 23(2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: CCTCATCTCC TGGGTCCCTT TCA 23(2) INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29: GTCCGCGCCA TGGCCATATA 20 (2)INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 30: ATGGGAGGCT GCCAGTCCTA ACCC 24 (2)INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:234 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 31: AATTTTTTTT TTCGACGGCC CAACGGAATTTTTTTTTTCG ACGGCCCAAC GGAATTTTTT 60 TTTTCGACGG CCCAACGGGA ATTCGGCTTAGCTAAGGTCA CCCAGACTTC ATGGACTTGT 120 CTATTTTCTT GCCCAAAGGG ATAGTTCCTCAGGTATTTGG GGACAGCATT CACCTCTTGC 180 AGGAGCTATG CCTGTGTGTT TGTGCTAAGTTGATACTTTC TGCGATGATC TCAC 234 (2) INFORMATION FOR SEQ ID NO: 32: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 266 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: TACCATCGGA GAAAGAAGAC CAAGCAAGGC TCAGGCAGCC ACCGCCTGCT TCGCACTGAG 60CCTCCTGACT CAGACTCAGA GTCCAGCACA GACGAAGAGG AATTTGGAGA ATTGGAAATC 120GCTCTCGTTT TGTCAAGGGA GACTATCCCG ATGCTGCAAG ATCTGCTGTC CCTCTGGCCT 180TTGTCATCCT CGCGCCTGCG TTGTGGCCTC TGTGGGCTTG GTGTGGAGCA AATGGCTCTC 240AAGGAGGACT GAGTCTCAAG GAAATT 266 (2) INFORMATION FOR SEQ ID NO: 33: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 300 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: AGCTAAGGTC AGGAGGTGTC TGAAGAATTG GCTGATGCAT GGCAGGGATG TTGTTGACCT 60GCTTTTAGAA CAATACTTCC ATTTAATTAT AGCATATCTT ATGTGTGTAT TAAAGCAGAG 120CCGATCTGGT GGGGCTCATT AAGTAAATGT ACTTACTGCA AAAGGTTCAA CTGGTGACCC 180CAGTTTTCCC CAGAAGCAAT ATGATAGGAC AGAGGCGACT CCTGCAAGTT GTCTCAGACT 240TCACACATAC ATTGTGACAT TCTCTGAGCA TGTGCACTGT ACATGATATG ACACTATCAA 300(2) INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 312 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: AGCTAAGGTC CACTACCTTGTGAAGATGTA TAAACACCTG AAATGTAGAA GCGATCCGTA 60 TGTCAAGATC GAGGGGAAGGACGCTGACGA CTGGCTGTGT GTGGACTTTG GGAGTATGGT 120 GATCCATTTG ATGCTTCCAGAAACCAGAGA AACCTATGAA TTAGAGAAAC TATGGACTCT 180 ACGTTCTTTT GATGACCTTAGCTAAGCCGA ATCAGCACAC TGGCGGCGTT ACTAGTGGAT 240 CGAGCTCGTA CAGCTGATGCATAGCTTGAG TATCTATAGG TTACTAATAG CTGGCTATCA 300 TGTCAAGCGT TC 312 (2)INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:281 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 35: AGCTAAGGTC AAAATAAAAG CTCAAGATGACATCAGTCCC ATTTGTCCTA AGTCCTGGTG 60 TTGTATGGAT GGTAAGCAGC AGCCAATTATGGTGACAGGT GATAGATCCA ATTTGTTAAC 120 ATTTCTCCAT CTCTAAGCCA TCCTTAAAGAAAATCATGAA TGGAGTCACA CCATCTTCAC 180 GGTAGTCCAG GAGAGCAACC ATACCATCTGGATTCATGTT TCACCAATAA AAACTGGTAG 240 TTATTGAATT AGCAAGGATG TGCTACTCTCTGCAGCTCAG C 281 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 240 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: AGCTAAGGTCTCATGCAATG GAACTTAATT CTTAGAACTG TAAGAATTAC ATCAAACATA 60 AAAGCCTCCCTATTAATGTA GTCCACAAAA CTGGCAGGTA TATATGCCTT CTGAATTTGT 120 CTCCAGTGACTTTGGTAAAT CTAACTAAAT TTTTAAAAAT TCTTAATGAA TTTATCGTCA 180 ACAACAACCACCTCTTGGAA AATTAACCCT TGCAGTGTCT GTGTTAGACT CAGAAGTCAA 240 (2)INFORMATION FOR SEQ ID NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:203 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 37: GAATTCGGCT TAGCTAAGGT CAGCGTGAAGTTTAAGCAGA CATGAGTCTG AAACAGTCTC 60 ATGACACATC TGATAGGATT TTTTAAGACTGCCTGGCTTA GTCTTACTGC TGTTAGTGTA 120 TATTAGGTGT TGTACACATT ATAAAGAAAATTATGTCTCA TTATCTTGTT TAAGTCAAGG 180 AAAATAGAGA ACTTTGGTCA AAT 203 (2)INFORMATION FOR SEQ ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:194 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 38: GAATTCGGCT TAGCTAAGGT CAGCGTGAAGTTTAAGCAGA CATGAGTCTG AAACAGTCTC 60 ATGACACATC TGATAGGATT TTTTAAGACTGCCTGGCTTA GTCTTACTGC TGTTAGTGTA 120 TATTAGGTGT TGTACACATT ATAAAGAAAATTATGTCTCA TTATCTTGTT TAAGTCAAGG 180 AAAATAGAGA ACTT 194 (2) INFORMATIONFOR SEQ ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 230 basepairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE:NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 39: GAATTCGGCT TAGCTAAGGT CAAAATACAC GGATTGCAATCACTTTTCTA AACAAAAGAA 60 ACAAAGTAAC TGCTGAGGTT AGCAAAGATG AGTTCTCGTCATACTGCCTT GTACTGTTTT 120 GTGAACTGTG TTATTAAAAA TCTGAGCTTA ACAAAATCTTTACAAGTCAC CTCATGAAAA 180 CAGCATTTGG CCAATAAGAG TTTAATTCCA CACCAGTGAGACCTTAGCCT 230 (2) INFORMATION FOR SEQ ID NO: 40: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 242 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40: GAATTCGGCTTTCTGCGATC CACTCTTTGA AGCTATTGGC AAGATATTCA GCAACATCCG 60 CATCAGCACGCAGAAAGAGA TATGAGGGAC ATTTCAAGGA TGAAAGGTTT TTTTCCCCCC 120 TTACTATTTCCTTGGTGCCA ATTCCAAGTT GCTCTCGCAG CAGCAAATTT ATGAATGGTT 180 TGTCTTGATCAAGAACAAAG AATTCATTCC CACCATTCTC ATATATACTA CTTTCTCTTC 240 TT 242 (2)INFORMATION FOR SEQ ID NO: 41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:240 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 41: GAATTCGGCT TTCTGCGATC CACTCTTTGAAGCTATTGGC AAGATATTCA GCAACATCCG 60 CATCAGCACG CAGAAAGAGA TATGAGGGACATTTCAAGGA TGAAAGGTTT TTTTCCCCCC 120 TTACTATTTC CTTGGTGCCA ATTCCAAGTTGCTCTCGCAG CAGCAAATTT ATGAATGGTT 180 TGTCTTGATC AAGAACAAAG AATTCATTCCACCATTCTCA TATATCTACG TCTCTTCTAG 240 (2) INFORMATION FOR SEQ ID NO: 42:(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 154 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: GAATTCGGCT TTCTGCGATC CTAGAGCAGG TAAGTGAAGA AGGCCAGTAA GTTTTAAGGA 60TGGCCTTGTT GCCTTCTATC AAGTTCTCTG GGACTTTGTA ATTTTGATTA CTACTATTGA 120TACATGGTTA TGGTCAGAAG GCCTCTTCTC CCTT 154 (2) INFORMATION FOR SEQ ID NO:43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 270 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: AGCTAAGGTC CGGACTCTAT GGCATGACCC CAAAAACATT GGCTGGAAAG ATTACACTGC 60CTACAGGTGG CACCTGATTC ACAGGCCTAA GACAGGCTAC ATGAGAGTCT TAGTGCATGA 120AGGAAAGCAA GTCATGGCTG ACTCAGGACC AATTTATGAC CAAACCTACG CTGGTGGACG 180GCTGGGCTGT TTGTCTTCTC CAAGAGATGG TCTATTCTCG GACCTCAAGT ATGAGTGCAG 240AGATGCTAGA GAGCAGGCTC AGTCTCAGCA 270 (2) INFORMATION FOR SEQ ID NO: 44:(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 285 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: TGACCATCGA GTGCATCAGC CTCATCGGGC TGGCCGTCGG GAAGGAGAAA TTCATGCAGG 60ATGCTTCAGA TGTGATGCAG CTATTGTTGA AGACACAGAC AGACTTCAAT GATATGGAAG 120ATGACGACCC CCAGATTTCT TACATGATCT CAGCATGGGC CAGGATGTGC AAAATCTTGG 180GAAAGAATTC CAGCAGTACC TTCCCGTGGT TATGGGGCCG CTGATGAAGA CTGCTTCAAT 240TAAGTCCTGA GTGCCTCTAG ACACCAGGAC ATGAGATATG AGGTA 285 (2) INFORMATIONFOR SEQ ID NO: 45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 260 basepairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE:NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 45: TGACCATCGT GTAGTTGGTG TGCTTGTTGT CGAAGATGAGGGCCTCCTGG ATGAGCTGGT 60 GCTGCTGCTC CAGCAGGTCC AGGCTGGGCT TGTAGTCCACGATGCTGCGC TCGTACTGCT 120 TCAGGTGGCT CAGCTGGTCT TCCAGAGTCC CGTTCATCTCAATGGAGATG CGCCCGATCT 180 CCTCCATCTT AGTCTGGATC CACGGCCCCA CCATATTGGCTTGGCTGGCG AACTGTCGGC 240 GAAGGCTGCA TTGGATTGCT 260 (2) INFORMATION FORSEQ ID NO: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 283 base pairs(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 46: TGACCATCGA ACACCCCAAC ACTCTCCACT ACCTGCCATTTCTTCCAGCC TTATCCACAC 60 CACCCCGTTT CTCCTGAAGA CTGATTTGCT TAGCAACTGCACTGAGCCAA CCCTGAAGAC 120 ACATGATTAT TGGTTGGGCT CCATTAAACA ACAAGCCTAGTGCTTGGGAA GGGGGGTGGG 180 GAGGGGAAGA GACGTGAGAA GCATGTTGGC GTAGACCTTGAGGCATGGAT GAAGCATCTG 240 CCGGCCTGAC CTGGTACAGG TGGCATCTGC ACTGCAGCAAGGC 283 (2) INFORMATION FOR SEQ ID NO: 47: (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 277 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL:NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINALSOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47: TGACCATCGA AGTGCAAAGGAAATGACTTG ATTTCATGAA GTATCTCCAG AAGTAACGCT 60 TTGTTTTCTG CATCCTGAACTTTATTCCCA GTGAAGAGCT GAAAATCTGG ACGCTCAAAA 120 AATGGAAGCA CTTTGGAGAGAGCCCTTAAC TCTATCAGGT ACAGGAAGTA CAAGTTCCTC 180 AGCCTTCGTG GGCCTTCTCCTTCAGTCAGA ATCCATCAAA GGTGCTGGAA CTCTGTGACA 240 TTGTGACCCA TTCTTTCAGCCAGTATCTGT AAGATAC 277 (2) INFORMATION FOR SEQ ID NO: 48: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 215 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48: GGGAACGAATGATCTGGAAC TGTGGCTTGT AGACAACCCA AATATCTTAG GTAGGTAAGA 60 AATTCCAGCATCACACTATA TAGGAAATAC TGTGCGAAAC TGACAGTTAA CTGTGCACAA 120 AGTTCAATGGCTTCAAAATA ATGTATAAAG GATAAGAAGA AACCAGTTTA CCATTTTGGT 180 ATTATTTTGGTTGCTTTGTA TAACTTCAAT AATTT 215 (2) INFORMATION FOR SEQ ID NO: 49: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 215 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: GGGAACGAAT GATCTGGAAC TGTGGCTTGT AGACAACCCA AATATCTTAG GTAGGTAAGA 60AATTCCAGCA TCACACTATA TAGGAAATAC TGTGCGAAAC TGACAGTTAA CTGTGCACAA 120AGTTCAATGG CTTCAAAATA ATGTATAAAG GATAAGAAGA AACCAGTTTA CCATTTTGGT 180ATTATTTTGG TTGCTTTGTA TAACTTCAAT AATTT 215 (2) INFORMATION FOR SEQ IDNO: 50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 50: GACGTAAGCC 10 (2) INFORMATION FOR SEQ ID NO:51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 189 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: CCACAAAGCA AGCTTCTGTC TGGAGTACAG CTCCTGTGAC TATGGGTACC ACAGGGCCTT 60TGCGTGCACT GCACACACAC AGGGATTGAG TCCTGGATGT TATGACACCT ATGCGGCAGA 120CATAGACTGC CAGTGGATTG ATATTACAGA TGTACAACCT GGAAACTACA TTCTAAAGGT 180CAGTGTAAA 189 (2) INFORMATION FOR SEQ ID NO: 52: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 227 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52: CTATCAATGAAGGGGGAGAT CACTGGGTAA GTTCGAATGC CCTCAGGCAA GGTGGCCCAG 60 CCTTCCATTACTGAATTCAA AGATGGCACT GTTACTGTAC GTTACTCACC CAGTGAAGCT 120 GGCCTGCATGAAATGGACAT TCGCTATGAC AATATGCATA TCCCAGGAAG CCCTCTGCAG 180 TTCTATGTTGATTATGTCAA CTGTGGCCAC ATCACTGCTT ATGGTCC 227 (2) INFORMATION FOR SEQ IDNO: 53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 373 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 53: TTAGCACCTC GACCACGAAA TGAGGAAGAT GCAACAGACGTGGTGGGCCT GGCTCAGGCT 60 GTAAACGCTC GGTCCCCACC TTCAGTAAAA CAGAACAGCTTGGATGAAGA CCTTATTCGG 120 AAGCTAGCTT ATGTTGCTGC TGGGGACCTG GCACCCATAAATGCTTTCAT TGGGGGCCTT 180 GCTGCCCAGG AAGTCATGAA GGCCTGCTCT GGAAAGTTTATGCCCATCAT GCAGTGGTTG 240 TACTTTGATG CTCTTGAATG TCTCCCAGAA CGGACAAAGAGGCTCTGACA GAGGAGAGTG 300 CCTCCCACGT CAGAACCGTT ACGATGGGCA GGTAGCTGTATTGGTCAGAC TTCAGGAGAA 360 GCTGAGAAGC AAA 373 (2) INFORMATION FOR SEQ IDNO: 54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 257 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 54: TTAGCACCTC CAATGGCTGG GTACCAGCCA GCCGCAATGTCCGCTCCACA AATTTGGAGT 60 CTGTGAGGTA CTGATTAACA TTTTCTGCTG GCTGCTTGAAAAGGCCTTCA AATTCATCCC 120 GGGCCCACTG AAGAGTGTGT TCGATGGCAT TGGGAAAGTTTTTCAGGGTA CAAATGGGGA 180 TGGATTTCTC TGGTGGATCC TGGCTAGACG TGATGGATTCTGTCAGGAAG GGGATTACCA 240 CCTGCACGTT GCCCTTT 257 (2) INFORMATION FOR SEQID NO: 55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 298 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 55: TTAGCACCTC ACACTCACAT GCCCTTCTAC ATAGAGACTGGTTAAACAGC CCTCCCTCCC 60 TTGTCCCGAC TTGACTTCCA GGCCCCTCTG CTTTCCTCTCACAACCACAC CAGGTCTGAT 120 GGAGTCCAGT GCCTGCAGTG ACCCAACATA GACTGCACTTTCACCTACCT ACTGGATGGT 180 CCTGCAGCCC AGACGGCTGC TCTTCTTTCT CATGGAGTTTCTCTCCTGCC TGAGATATGC 240 TATCTGGTCT GCCCCTGTGT AGCTCCCATG GGATCCCTTAAAATCGATCC TTTTTTAA 298 (2) INFORMATION FOR SEQ ID NO: 56: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 337 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56: TTAGCACCTCGTGAGGAGAC TGTTGTCCAC AGGCCAGCTA GTGGTACCCT ACTGAGAAGT 60 TGGGTTTTGGTTTTGTTTCC CTTGAAGGGT CGCTGTTAGA GGATGGAAGT AACTTCTAAT 120 TCTTGATCTGTTTGTTGGTC TTGTTTTCAG TACTTTTTGC CAGTTGTATA CACTTGGAGA 180 GGGAATTTGTATGCCTGTAA TCTTGTTCTT GAGGTCAGAA ATTCAAAACA TTGGGAGCTT 240 TTGTTGTAAAGGTTAAACTG TGAATCCATA TAGCAAATGC AGATCCTTTT ACAGTGTAAA 300 CCACATTTCCTGCCTCAGCC TAAAGCACTG GTCATTT 337 (2) INFORMATION FOR SEQ ID NO: 57: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 333 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57: ACCTGCATGC CTAAAGGAGT AGGCTTAGGG GTGGGGAGAG AGAAGGCATA GGCTTTTCTA 60GTTATACAAA GCTGTGTAAG GCAAGGTTCC TTTCTACTAA ATGGTCAGCT GTCACTACAT 120TTATACTTTT GTATGTCATA AACCCTTTCT TTCATTCCTC CCTGGGTAAC CAGGACAATC 180GGAGGGCAGT GTGTTACTGG GATTAGAGGA CTAGCAATAC TGGGTAACCC GCCTAAGCTG 240GAAGGTGACG TAATACGTTT CTTTAAAGAT TCAGTCAGTC AAGCAGTTTA GCAATATCAA 300AATGTCTGGC TGTTTGGTCC AGTGTACACT GTT 333 (2) INFORMATION FOR SEQ ID NO:58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 296 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58: GCTATCTGCG AAACTACAGA AAGGAAGACA GCTTGGCCCA GCGCGGTGAA GTTCAGAATT 60CACTAGGTAG TTGTTGTTGG TTGACTTGGA GGTAGCTGGG TAATCAACAG CTTTCACTTT 120AGATTCAATG TGAACCGCAG AGTTACTCAT GACCAAGAGT CTGGCAAACT CATTAATGCT 180GTTTAATACT TGTTTGATAT TTTTTCACCT TTTGAGCCCT TTTCCCAAAG AATTCAATAT 240CAGTTTAGTA GCAACAGTAC AGTTGCCATT TAAATTGGTT TAGTTGCAGT ATAGCA 296 (2)INFORMATION FOR SEQ ID NO: 59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:296 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 59: GCTATCTGCG AAACTACAGA AAGGAAGACAGCTTGGCCCA GCGCGGTGAA GTTCAGAATT 60 CACTAGGTAG TTGTTGTTGG TTGACTTGGAGGTAGCTGGG TAATCAACAG CTTTCACTTT 120 AGATTCAATG TGAACCGCAG AGTTACTCATGACCAAGAGT CTGGCAAACT CATTAATGCT 180 GTTTAATACT TGTTTGATAT TTTTTCACCTTTTGAGCCCT TTTCCCAAAG AATTCAATAT 240 CAGTTTAGTA GCAACAGTAC AGTTGCCATTTAAATTGGTT TAGTTGCAGT ATAGCA 296 (2) INFORMATION FOR SEQ ID NO: 60: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 273 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60: GCTATACTGC AACTAAACCA ATTTAAATGG CAACTGTACT GTTGCTACTA AACTGATATT 60GAATTCTTTG GGAAAAGGGC TCAAAAGGTG AAAAAATATC AAACAAGTAT TAAACAGCAT 120TAATGAGTTT GCCAGACTCT TGGTCATGAG TAACTCTGCG GTTCACATTG AATCTAAAGT 180GAAAGCTGTT GATTACCCAG CTACCTCCAA GTCAACCAAC AACAACTACC TAGTGAATTC 240TGAACTTCAC CGCGCTGGGC CAAGCTGTCT TCC 273 (2) INFORMATION FOR SEQ ID NO:61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 322 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61: GCTATACTGC CCACCACATT GCCACACTCG GAATGACATT TCTATATTTT CACCTCCCCA 60GATTTCCATT TCTTCATCGT AACTTCCAAT GTGCTCAAAA TATTTTTTAG ATATAGAAAA 120AAGGCCTCCT GCAAAGGTGG GGGTCTTAAT TGGGTAGGTT TCATCTTTCC TTCTTTGCTT 180CTCATGATCA GGAAGTGACT CCCAGCCAAA GGAAAGGCTC CAGTCAAAAT TTCCACGGTT 240ATGGTTGCTT CCGTACGGAG AAGGCTTGTT GAATTCAAAT GTGTTTAGAT CTATGGATGC 300GATGTCTGGA CTCACCACGG CA 322 (2) INFORMATION FOR SEQ ID NO: 62: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 262 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62: GCTATACTGC TGAAGGAGAT CATTTTGGTG GATGATGCTA GTGTAGACGA CTACCTGCAT 60GAAAAGCTGG AGGAATACAT AAAACAGTTT TCTATTGTGA AAATAGTCAG GCAGCAAGAA 120AGGAAAGGCC TGATCACCGC GCGGTTGCTA GGGGCAGCTG TAGCAACTGC CGAGACGCTC 180ACGTTCTTAG ATGCTCACTG TGAGTGCTTC TATGGCTGGC TGGAACCTCT GCTGGCCAGG 240ATAGCTGAGA ACTACACTGC CG 262 (2) INFORMATION FOR SEQ ID NO: 63: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 295 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63: AGTTGCCAGG GGGCAGCTCA CGGCGCAGCT CATCCTCTGT GATGTAATTC TTATCTCCAG 60CCAGGATCTT GAAGGAAGCC ATGACCTGAT CTGCAGTATC AGTATCTGCC GTCTCTCGGG 120ACATAAAGTC GATGAAGGCC TGGAACGTCA CTACCCCCAA GCGGTTGGGG TCTACAATGC 180TCATGATTCG GGCAAACTCT GCCTCTCCCA TGTTGTAACC CATGGAGATA AGGCAGGCGC 240GGAAATCGTC TGTGTCCATC ATGCCCGTCT TCTTCCGGTC AAAGTGGTTG AAAGA 295 (2)INFORMATION FOR SEQ ID NO: 64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:287 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 64: AAGCCGTGTC GCTGAACTGG GAGGACACACTGCTCACCCT AGAAGGCTCT GGCTGACCCT 60 CCGCCCGGTT AAACAGGGAC TTTGTGGCCATGTGCTGGCG ACACAGGTCC TGGTACTCAA 120 AAGTAGTGTC ACCATGGGCC CCCTCCGGCCCCAGCGCTGC CAGGCGTCCT TATCCCGCTG 180 TCTCGAATGA TGGCGCATAC CAAGGCCACTGAAAGCCACT AGCAGCCCAG CGACGCCTGC 240 CAGGGCCACT AGAGTAAGCA GCACTGAGCGCATGGGAGAT ATGCCAT 287 (2) INFORMATION FOR SEQ ID NO: 65: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 332 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65: AAGCCGTGTCTGGACGTCCG TGTGTCCGGC TCTTGCTCAC GCAGTCATGG CCTCCGGAAC 60 GCGCAAATCGGAAAGTCGGC TCCTGACTTC ACGGCCACAG CGGTGGTGGA TGGTGCCTTC 120 AAGGAAATCAAGCTTTCGGA CTACAGAGGG AAGTACGTTG TCCTCTTTTT CTACCCACTG 180 GACTTCACTTTTGTTTGCCC CACGGAGATC ATCGCTTTTA GCGACCATGC TGAGGACTTC 240 CGAAAGCTAGGCTGCGAGGT GCTGGGAGTG TCTGTGGACT CTCAGTTCAC CCACCTGGCG 300 TGGATCAATACCCCACGGAA AGAGGGAGGC TT 332 (2) INFORMATION FOR SEQ ID NO: 66: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 331 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66: AAGCCGTGTC GGAGGGCACC AAGGCTGTCA CCAAGTACAC CAGCTCCAAG TGAGTGCTCA 60AGACTCAGCT CTTAACCCAA AGGCTCTTTT CAGAGCCACT CAAGACTTCA AAATTGGAGC 120TTTAATGCTG ACTTAGTGAC TACCGGGAAA ATAACTGACT TCATCTGCAG GATTGTGTAC 180AAACACTTAT GGTTTAGTAA ATCGAAAAGA TAGACATTGC CCATCAGTTC TGTCTGGTCC 240ACTTAAATAT GCTTTTTTCT TAGAAGTTCT AAGAACCCTG TCAATAACCT ATCTAGGTCC 300AGTCCTTGAG TTCAAAGGCC AAATACCAAT G 331 (2) INFORMATION FOR SEQ ID NO:67: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 359 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67: CAACGCTCAG GATGTAAGCT GTTTCCAGCA CCTGGTTCAA GCGAATGTAA GAAATAAGAA 60GGTGTTGAAA GATGCCGTGA ATAACATTAC AGCAAAGGGG ATCACAGATT ACAAGAAAGG 120CTTTAGCTTT GCCTTCGAAC AGCTACTTAA TTATAATGTT TCCAGAGCTA ATTGCAATAA 180GATTATCATG TTATTCACGG ATGGAGGAGA AGAGAGAGCC CAGGAGATAT TTGCCAAATA 240CAATAAAGAC AAAAAAGTCC GTGTGTTTAC ATTTTCCGTC GGTCAACATA ATTATGACAG 300AGGACCTATT CAGTGGATGG CTTGTGAAAT AAAGGTTACT ATTATGAGAT TCCTCCATT 359 (2)INFORMATION FOR SEQ ID NO: 68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:317 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 68: TCAACGCTCA TCACACCAAG AATCAACTGGTTCTTCAAGT TTGTCTTATT TTCAGATTGG 60 CCAGTGACGT TGAAGACTGG TAGAGTTCCAGTAATGACAA GTCCCAGTTC CAGGGCATCC 120 AAATACACAT TTGTCCATTG AACTTGCTTCGCTTTGTCAC CAGCTAAAAC CATTGGTCTT 180 CCCAGAACAT CTAGATATTC CTGAGTATTGATTCTTATTG CACCAATGGA GGGAATCTCA 240 TAATAGTAAC CTTTATTTTC ACAAGCCATCCACTGAATAG GTCTCTGTCA TAATTATGTT 300 GACCGACGGA AATGTAA 317 (2)INFORMATION FOR SEQ ID NO: 69: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:317 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 69: TAACGCTCAG GAGAAGAATA GGAATGCAGAGAACTCTGCC ACAGCCCCCA CGCTCCCGGG 60 CAGCACCTCA GCCACCACCG CAACCACCACCCCTGCTGTA GATGAAAGCA AGCCTTGGAA 120 CCAGTATCGC TTGCCTAAGA CTCTTATACCTGACTCCTAC CGGGTGATCT TGAGACCCTA 180 CCTCACCCCC AACAATCAGG GCCTGTACATCTTCCAAGGC AACAGTACTG TTCGCTTTAC 240 CTGCAACCAG ACCACGGATG TCATTATCATCCACAGCAAA AAGCTCAACT ACACCCTCAA 300 AGGAAACCAC AGGGTGG 317 (2)INFORMATION FOR SEQ ID NO: 70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:287 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 70: CGAGTCAGAC GGCTTCAGCA TCGAGACCTGTAAGATCATG GTGGACATGC TGGATGAAGA 60 TGGGAGTGGC AAGCTTGGCC TGAAGGAGTTCTACATCCTC TGGACGAAGA TTCAGAAATA 120 CCAAAAAATC TACCGGGAAA TCGATGTGGACAGGTCTGGA ACTATGAATT CCTACGAGAT 180 GCGGAAAGCA CTGGAAGAAG CAGGTTTCAAGCTGCCCTGT CAACTCCATC AAGTCATCGT 240 TGCCCGGTTT GCAGACGACG AGCTAATCATCGACTTTGAC AATTTTG 287 (2) INFORMATION FOR SEQ ID NO: 71: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 311 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71: CGAGTCAGACAACCTGTTCA AGTGGGGTGG GGACCATCCA CGGAGCAGCC GGCACCGTAT 60 ATGAAGACCTGAGGTACAAA CTCTCCCTAG AGTTCCCCAG CGGCTACCCT TACAACGCAC 120 CCACAGTGAAGTTCCTCACA CCCTGCTACC ACCCCAACGT GGACACCCAG GGCAACATCT 180 GCCTGGACATCCTCAAGGAT AAGTGGTCTG CACTATATGA TGTCAGGACT ATCTTGCTCT 240 CTATCCAGAGCCTGCTAGGA GAACCCAACA TCGATAGCCT TTGAACACAC ACGCTGCGGA 300 ACTCTGGAAA A311 (2) INFORMATION FOR SEQ ID NO: 72: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 352 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72: TATGAGTCCG GAGCGACGGCTACGAGTGTG AACTGTTCCA GCCCCGAGCG ACACACCAGA 60 AGTTATGACT ACATGGAAGGAGGGGATATA AGGGTGAGAA GACTGTTCTG TCGCACCCAG 120 TGGTACCTGA GGATTGACAAACGAGGCAAA GTGAAAGGGA CCCAGGAGAT GAAGAACAGC 180 TACAACATCA TGGAAATCAGGACCGTGGCA GTTGGAATTG TGGCAATCAA AGGGGTGGAA 240 AGTGAATACT ATCTTGCCATGAACAAGGAA GGGAAACTCT ATGCAAAGAA AGAATGCAAT 300 GAGGATTGCA ACTTCAAAGAACTGATTCTG GAAAACCATT ATAACACCTA TG 352 (2) INFORMATION FOR SEQ ID NO:73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 317 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73: TATGAGTCCG AGGAGGAGCA CAATGCTGGG AGTGTGGAAA GCCAGGTTGT CCCCAGCACA 60CACCGAGTGA CCGATTCCAA GTTCCATCCA CTCCATGCCA AGATGGATGT CATCAAAAAA 120GGCCACGCCA GGGACAGCCA GCGCTACAAA GTTGACTATG AGTCTCAAAG CACAGACACC 180CAGAACTTCT CCTCCGAGTC TAAGCGGGAG ACAGAATACG GTCCCTGCCG CAGAGAAATG 240GAGGACACAC TGAATCATCT GAAGTTCCTC AATGTGCTGA GTCCAGAGTC TCACATCCAA 300ACTGTGACAA GAAGGGG 317 (2) INFORMATION FOR SEQ ID NO: 74: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 247 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74: TCGCCCGGGACTTCATGCGA TTGAGAAGAT TGTCTACCAA ATATAGAACA GAAAAGATTT 60 ATCCCACAGCCACTGGAGAA AAAGAAGAAA ATGTTAAAAA GAACAGATAT AAGGACATAC 120 TGCCATTTGATCACAGCCGA GTTAAGTTGA CTTTGAAGAC TCCATCCCAA GATTCAGATT 180 ATATCAATGCAAATTTTATT AAGGGTGTGT ATGGGCCAAA AGCATATGTG GCAACCCAAG 240 GGCCTTT 247(2) INFORMATION FOR SEQ ID NO: 75: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 256 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75: TGTGGAAAGC CAGGTTGTCCCCAGCACACA CCGAGTGACC GATTCCAAGT TCCATCCACT 60 CCATGCCAAG ATGGATGTCATCAAAAAAGG CCACGCCAGG GACAGCCAGC GCTACAAAGT 120 TGACTATGAG TCTCAAAGCACAGACACCCA GAACTTCTCC TCCGAGTCTA AGCGGGAGAC 180 AGAATACGGT CCCTGCCGCAGAGAAATGGA GGACACACTG AATCATCTGA AGTTCCTCAA 240 TGTGCTGAGT CCAGAG 256(2) INFORMATION FOR SEQ ID NO: 76: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 383 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76: TGACCATCGA AGTGCAAAGGAAATGACTTG ATTTCATGAA GTATCTCCAG AAGTAACGCT 60 TTGTTTTCTG CATCCTGAACTTTATTCCCA GTGAAGAGCT GAAAATCTGG ACGCTCAAAA 120 AATGGAAGCA CTTTGGAGAGAGCCCTTAAC TCTATCAGGT ACAGGAAGTA CAAGTTCCTC 180 AGCCTTCGTG GGCCTTCTCCTTCAGTCAGA ATCCCATCAA AGCGCTGCTG GAACTCTGTG 240 ACATTGTGAC CCCATTTCTTTTCCAGCCAA GTATCTTGTA AAAGATACCT TGCACTCAAA 300 TGCACATTAA TGCTTGCGTGCAGGCCAGAT ATAAGTCTGT AGAATCGCTC TTTCTACACA 360 GAGGCCTTCT AGCCAGTTGTAAA 383 (2) INFORMATION FOR SEQ ID NO: 77: (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 400 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL:NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINALSOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77: CTGCTTGATG CTAAGCCCGGCAGCCTGTGT TTCATCTACA GGATGCACAA CATAAAAGAA 60 AAGATCTGAT TCCCGCAGGTTCTCTTCTGA CCTACACACA CACACACTAA AATAACATTT 120 AAAAATATGT GCCAAATTATATTTGTTCGG GTGCCACCTT CCACCAGCTT ACCACTACGG 180 TAGAACTGTC AAATTCATCTCCCTGAATTT GTCTTAAAGG GGTGTCCATG CACAGGCCCA 240 AGAGTCACCT CCAATGAAATAAATGTAATA CTGAAGTATG CCATGATGTT TGTTGTTTTC 300 TTTCATCGTA AGCCTGTAAGCAGGAAAAAT AGTAATAGAT AGAATAGAGA CTTACCAGTG 360 GTCGATGGCC TGGTCAGTCTGTGCGGTGAC TAGGACCAGG 400 (2) INFORMATION FOR SEQ ID NO: 78: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 343 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78: ACCTGCATGC CGAGTGTGAC GCCTTTGAGG AGAAGATCCA GGCTGCCGGA GGGATCGAAC 60TCTTTGTCGG AGGCATTGGC CCCGATGGAC ACATTGCCTT CAATGAGCCA GGCTCCAGCC 120TGGTGTCCAG GACCCGTGTG AAGACTCTGG TTATGGACAC CATCCTGGCC AACGCTAGGT 180TCTTTGATGG TGATCTTGCC AAGGTGCCCA CCATGGCCCT GACAGTGGGT GTCGGCACTG 240TCATGGATGC TAAAGAGGTG ATGATCCTCA TCACAGGCGC TCACAAGGCC TTTGCTCTGT 300ACAAAGCCAT CGATGGAGGC GTGAACCACA TGTGGACGGT GTG 343 (2) INFORMATION FORSEQ ID NO: 79: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 337 base pairs(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 79: GCTATACTGC AATGTTAGGG GAATGAACGC GTTTTCCTACTGCACTGGGG ACTTTTAGAT 60 AGGTTAATGA AAGGCCTTTT ATTCTGTTAC TGGACACGAAAACTTTGTCT AATTTCTTAT 120 ACTCTATTGT ACGTTTACAG TCGCAGCACT AAAATGGAAGACATCAAACA TTTTTAACAG 180 AAAAAAAAAA AGATGTAAAA ACTAACTAAG GACTATTTATTGATAATGTT TTGCTACTCC 240 TGTCAGACAA TGGCTATAAA CTGAATTAGG CAGTCTTAAAAAAAAAAAAA GAAAAAAAAG 300 AAAAAAGAAA AAAAGAAAAG AAAAGAAAAA AAACTGG 337(2) INFORMATION FOR SEQ ID NO: 80: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 371 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80: AGCTAAGGTC GGGTACTCTGATACTTCAGA GTTTAAAATC ATCAGCCCTT GTAGATCTAT 60 TCCTAAATCT TATGAAAATGCTCAGATGTT TACACAGCTG TGAAACAGGG TCAGTTCAGA 120 TCGCTGATGG CTTGAGAATGTGTTTCTTGT TGACATCAGG AACTGGAAAT GTTTACTTCC 180 CGTCATTTAT GAGTCATCAAGTATCTCGGC TCTTTTAAGA GCGCAAGATA AAACAAGCTT 240 AAACCAGGTG ATAAGAGCAGAGTCCACTTG AGTCTGAGCT CACCCGAGAA CTTGCTATCG 300 AGGACATTTG GAATGGGAGTGTGCAGGCTT CCTTCAGTTA CTGAATGAGT CCATCTGCTA 360 GTCACCTTGA C 371 (2)INFORMATION FOR SEQ ID NO: 81: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:319 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 81: AGCTAAGGTC CAGGGGGCAA AGCGGTGACGTGTGCACATC GATATGAGAA ACGGCAGCAC 60 GTCAACACGA AGCAGGAGTC GCGGGATATCTTTGGAAGAT GTTATGTCCT AAGTCAGAAT 120 CTCAGAATTG AAGATGATAT GGACGGAGGAGACTGGAGTT TCTGCGATGG CCGGTTGAGA 180 GGCCATGAAA AGTTTGGCTC CTGTCAGCAAGGAGTAGCGG CTACTTTCAC TAAGGACTTT 240 CATTACATTG TTTTTGGAGC CCCAGGGACTTACAACTGGA AAGGGATCGT CGTGTAGAAC 300 AAAAGAATAA CACTTTTTT 319 (2)INFORMATION FOR SEQ ID NO: 82: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:368 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 82: AAGCCGTGTC TGTGCTCAAG GAAGAAACCCACTGGACCAA CTTCTGTCAG AAAGGAAAAC 60 CTTGTTCAAA GTTTCAGGAC CCTGTTCTTTGCTTATTTGC ACATGGTCAC CTTGGTCTGA 120 GCTAGCCACC ATTGTCACCC ACAGCTGCAAAGAAAGCAGA CCTTAGGAAA CACTGTCACG 180 GCTGAGTGTG ACTGCCTTGT TCATCCCCTGGACTGGTACT GTGTTGCCTG CAGTACCATT 240 GGGATCCCAT AGCAAGAGAG GGAGAGGGAGATGTTAGTTA GCCTTTGCTA CGAACCAAGC 300 TGTCCCAAGT CTCAACAGCT AAACAGGTATTCATTTACCA TGATTCTATG GTTAGCTAAG 360 CTCTTGAG 368 (2) INFORMATION FORSEQ ID NO: 83: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 340 base pairs(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 83: CTTTCTACCC TGGAGGATGT GCTTGAGGCA CACTGCTCCTGTGCTCTCCA CTTGAGGCAT 60 AAGCCCAGTC AGTTGTGCAT AGATGATTAA CCTCTGACCCCTAAAGATGG TAAGTTGCTC 120 TGGAGAAAGC ATTTTAACAG ACAAACCAGG AGGCAAATCCCAACTTAGAG AGATGTTATC 180 CACTGCACAC TGTAGAGCAA ACTTGAGAGA CCCAAGAGCCTTGGTCTGCA TCCTGTCCTT 240 GCCTGTGATA AACACTCGAG TACCCCCTGA TACCGGGCGATATTTTTGAT TAACTGGTCG 300 AGGCTCCTTG TCCAATTCCA AAAGAGAACA TCTGTGTTTC340 (2) INFORMATION FOR SEQ ID NO: 84: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 252 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84: TGGTAAAGGG CATCTGTAAATACACTCTAT GAGGAAATTA AAACTTGAAC ATGGCAGTCT 60 GACATTGCAA AACAAAACAAAACAAAACTG ACCCTCCAAT AGCAGCGAAA ACAACGTGAA 120 AGATACAAAG CAATGAGAATCTGGTTCTGA ACGCCTGGGA TCCTGGGAGT CATCGGTAGC 180 AGCGCCATGA GAGGAGCCGTGGCCTGTCCC ATGTGGTCCC ACCTTCACCT CTTCCCTCAC 240 ATCCCTCTTA AG 252 (2)INFORMATION FOR SEQ ID NO: 85: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:348 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 85: TGGTAAAGGG GGCAAGGGCA AAGGCACGGGAGACAGAGGC CACTGCATCT GTACCCACAT 60 CAGACATGTT TGTCCATTTT CTCTCATTTGGCCTTAGACC ATTGGCAAGA GTAAATGCTC 120 TTAGTCCCGT TATCTAGAAA TTTCTTCCTTTGGGGAGAAC CACTTATAGA CAATATCAGC 180 TCTCTACAAA TAACACGAAA GGTCGTAACACAGCAAGTGA CCAGAAAGTG CCCGTCCTTG 240 CGGCTCTGAT CCACGTGGCT CTCCGTAGACAAATTGTTTT TTCTTGTAGG GATATCTGTT 300 TTGCTTCTGA ACTTTCTTAC AAGTGTTTGGGACTCTTCGG GTGGCGTT 348 (2) INFORMATION FOR SEQ ID NO: 86: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 351 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86: TGGTAAAGGGTCAAGTGTTC GATCAGAGTG GAGCTCCATT ACCGAATGTA ATCGTGGAAG 60 TCCAAGACAGAAAGCATATC TGCCCGTTTA GAACCAACAA GCTTGGAGAA TACTATCTGC 120 TTCTGCTGCCCGGGTCCTAC GTGATCAATG TTACAGTCCC TGGACACGAC TCCTACCTCA 180 CGAAGCTTACTATTCCAGGG AAATCCCAGC CCTTCAGTGC TCTTAAAAAG GATTTTCACC 240 TCCCGCTGCGATGGCAGCCG GATTCCATCT CCGTATCCAA TCCTTCGTGC CGATGATTCC 300 GCTGTACAAATTCATGCCAA GCCACTCGGC TGCCACAAAG CCTAGTCTGG G 351 (2) INFORMATION FORSEQ ID NO: 87: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 242 base pairs(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 87: GAATTCGGCT TTCTGCGATC CACTCTTTGA AGCTATTGGCAAGATATTCA GCAACATCCG 60 CATCAGCACG CAGAAAGAGA TATGAGGGAC ATTTCAAGGATGAAAGGTTT TTTTCCCCCC 120 TTACTATTTC CTTGGTGCCA ATTCCAAGTT GCTCTCGCAGCAGCAAATTT ATGAATGGTT 180 TGTCTTGATC AAGAACAAAG AATTCATTCC CACCATTCTCATATATACTA CTTTCTCTTC 240 TT 242 (2) INFORMATION FOR SEQ ID NO: 88: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 240 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88: GAATTCGGCT TTCTGCGATC CACTCTTTGA AGCTATTGGC AAGATATTCA GCAACATCCG 60CATCAGCACG CAGAAAGAGA TATGAGGGAC ATTTCAAGGA TGAAAGGTTT TTTTCCCCCC 120TTACTATTTC CTTGGTGCCA ATTCCAAGTT GCTCTCGCAG CAGCAAATTT ATGAATGGTT 180TGTCTTGATC AAGAACAAAG AATTCATTCC ACCATTCTCA TATATCTACG TCTCTTCTAG 240(2) INFORMATION FOR SEQ ID NO: 89: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 687 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89: ACGAGGGGAA ACCTCCTCAGAGCCTGCAGC CAGCCACGCG CCAGCATGTC TGGGGGCAAA 60 TACGTAGACT CCGAGGGACATCTCTACACT GTTCCCATCC GGGAACAGGG CAACATCTAC 120 AAGCCCAACA ACAAGGCCATGGCAGACGAG GTGACTGAGA AGCAAGTGTA TGACGCGCAC 180 ACCAAGGAGA TTGACCTGGTCAACCGCGAC CCCAAGCATC TCAACGACGA CGTGGTCAAG 240 ATTGACTTTG AAGATGTGATTGCAGAACCA GAAGGGACAC ACAGTTTCGA CGGCATCTGG 300 AAGGCCAGCT TCACCACCTTCACTGTGACA AAATATTGGT TTTACCGCTT GTTGTCTACG 360 ATCTTCGGCA TCCCAATGGCACTCATCTGG GGCATTTACT TTGCCATTCT CTCCTTCCTG 420 CACATCTGGG CGGTTGTACCGTGCATCAAG AGCTTCCTGA TTGAGATTCA GTGCATCAGC 480 CGCGTCTACT CCATCTACGTCCATACCTTC TGCGATCCAC TCTTTGAAGC TATTGGCAAG 540 ATATTCAGCA ACATCCGCATCAGCACGCAG AAAGAGATAT GAGGGACATT TCAAGGATGA 600 AAGGTTTTTT TCCCCCCTTACTATTTCCTT GGTGCCAATT CCAAGTTGCT CTCGCAGCAG 660 CAAATTTATG AATGGTTTGTCTTGATC 687 (2) INFORMATION FOR SEQ ID NO: 90: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 560 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90: Met GluCys Leu Tyr Tyr Phe Leu Gly Phe Leu Leu Leu Ala Ala Arg 1 5 10 15 LeuPro Leu Asp Ala Ala Lys Arg Phe His Asp Val Leu Gly Asn Glu 20 25 30 ArgPro Ser Ala Tyr Met Arg Glu His Asn Gln Leu Asn Gly Trp Ser 35 40 45 SerAsp Glu Asn Asp Trp Asn Glu Lys Leu Tyr Pro Val Trp Lys Arg 50 55 60 GlyAsp Met Arg Trp Lys Asn Ser Trp Lys Gly Gly Arg Val Gln Ala 65 70 75 80Val Leu Thr Ser Asp Ser Pro Ala Leu Val Gly Ser Asn Ile Thr Phe 85 90 95Ala Val Asn Leu Ile Phe Pro Arg Cys Gln Lys Glu Asp Ala Asn Gly 100 105110 Asn Ile Val Tyr Glu Lys Asn Cys Arg Asn Glu Ala Gly Leu Ser Ala 115120 125 Asp Pro Tyr Val Tyr Asn Trp Thr Ala Trp Ser Glu Asp Ser Asp Gly130 135 140 Glu Asn Gly Thr Gly Gln Ser His His Asn Val Phe Pro Asp GlyLys 145 150 155 160 Pro Phe Pro His His Pro Gly Trp Arg Arg Trp Asn PheIle Tyr Val 165 170 175 Phe His Thr Leu Gly Gln Tyr Phe Gln Lys Leu GlyArg Cys Ser Val 180 185 190 Arg Val Ser Val Asn Thr Ala Asn Val Thr LeuGly Pro Gln Leu Met 195 200 205 Glu Val Thr Val Tyr Arg Arg His Gly ArgAla Tyr Val Pro Ile Ala 210 215 220 Gln Val Lys Asp Val Tyr Val Val ThrAsp Gln Ile Pro Val Phe Val 225 230 235 240 Thr Met Phe Gln Lys Asn AspArg Asn Ser Ser Asp Glu Thr Phe Leu 245 250 255 Lys Asp Leu Pro Ile MetPhe Asp Val Leu Ile His Asp Pro Ser His 260 265 270 Phe Leu Asn Tyr SerThr Ile Asn Tyr Lys Trp Ser Phe Gly Asp Asn 275 280 285 Thr Gly Leu PheVal Ser Thr Asn His Thr Val Asn His Thr Tyr Val 290 295 300 Leu Asn GlyThr Phe Ser Leu Asn Leu Thr Val Lys Ala Ala Ala Pro 305 310 315 320 GlyPro Cys Pro Pro Pro Pro Pro Pro Pro Arg Pro Ser Lys Pro Thr 325 330 335Pro Ser Leu Gly Pro Ala Gly Asp Asn Pro Leu Glu Leu Ser Arg Ile 340 345350 Pro Asp Glu Asn Cys Gln Ile Asn Arg Tyr Gly His Phe Gln Ala Thr 355360 365 Ile Thr Ile Val Glu Gly Ile Leu Glu Val Asn Ile Ile Gln Met Thr370 375 380 Asp Val Leu Met Pro Val Pro Trp Pro Glu Ser Ser Leu Ile AspPhe 385 390 395 400 Val Val Thr Cys Gln Gly Ser Ile Pro Thr Glu Val CysThr Ile Ile 405 410 415 Ser Asp Pro Thr Cys Glu Ile Thr Gln Asn Thr ValCys Ser Pro Val 420 425 430 Asp Val Asp Glu Met Cys Leu Leu Thr Val ArgArg Thr Phe Asn Gly 435 440 445 Ser Gly Thr Tyr Cys Val Asn Leu Thr LeuGly Asp Asp Thr Ser Leu 450 455 460 Ala Leu Thr Ser Thr Leu Ile Ser ValPro Asp Arg Asp Pro Ala Ser 465 470 475 480 Pro Leu Arg Met Ala Asn SerAla Leu Ile Ser Val Gly Cys Leu Ala 485 490 495 Ile Phe Val Thr Val IleSer Leu Leu Val Tyr Lys Lys His Lys Glu 500 505 510 Tyr Asn Pro Ile GluAsn Ser Pro Gly Asn Val Val Arg Ser Lys Gly 515 520 525 Leu Ser Val PheLeu Asn Arg Ala Lys Ala Val Phe Phe Pro Gly Asn 530 535 540 Gln Glu LysAsp Pro Leu Leu Lys Asn Gln Glu Phe Lys Gly Val Ser 545 550 555 560 (2)INFORMATION FOR SEQ ID NO: 91: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:2669 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 91: CAGATGCCAG AAGAACACTG TTGCTCTTGGTGGACGGGCC CAGAGGAATT CAGAGTTAAA 60 CCTTGAGTGC CTGCGTCCGT GAGAATTCAGCATGGAATGT CTCTACTATT TCCTGGGATT 120 TCTGCTCCTG GCTGCAAGAT TGCCACTTGATGCCGCCAAA CGATTTCATG ATGTGCTGGG 180 CAATGAAAGA CCTTCTGCTT ACATGAGGGAGCACAATCAA TTAAATGGCT GGTCTTCTGA 240 TGAAAATGAC TGGAATGAAA AACTCTACCCAGTGTGGAAG CGGGGAGACA TGAGGTGGAA 300 AAACTCCTGG AAGGGAGGCC GTGTGCAGGCGGTCCTGACC AGTGACTCAC CAGCCCTCGT 360 GGGCTCAAAT ATAACATTTG CGGTGAACCTGATATTCCCT AGATGCCAAA AGGAAGATGC 420 CAATGGCAAC ATAGTCTATG AGAAGAACTGCAGAAATGAG GCTGGTTTAT CTGCTGATCC 480 ATATGTTTAC AACTGGACAG CATGGTCAGAGGACAGTGAC GGGGAAAATG GCACCGGCCA 540 AAGCCATCAT AACGTCTTCC CTGATGGGAAACCTTTTCCT CACCACCCCG GATGGAGAAG 600 ATGGAATTTC ATCTACGTCT TCCACACACTTGGTCAGTAT TTCCAGAAAT TGGGACGATG 660 TTCAGTGAGA GTTTCTGTGA ACACAGCCAATGTGACACTT GGGCCTCAAC TCATGGAAGT 720 GACTGTCTAC AGAAGACATG GACGGGCATATGTTCCCATC GCACAAGTGA AAGATGTGTA 780 CGTGGTAACA GATCAGATTC CTGTGTTTGTGACTATGTTC CAGAAGAACG ATCGAAATTC 840 ATCCGACGAA ACCTTCCTCA AAGATCTCCCCATTATGTTT GATGTCCTGA TTCATGATCC 900 TAGCCACTTC CTCAATTATT CTACCATTAACTACAAGTGG AGCTTCGGGG ATAATACTGG 960 CCTGTTTGTT TCCACCAATC ATACTGTGAATCACACGTAT GTGCTCAATG GAACCTTCAG 1020 CCTTAACCTC ACTGTGAAAG CTGCAGCACCAGGACCTTGT CCGCCACCGC CACCACCACC 1080 CAGACCTTCA AAACCCACCC CTTCTTTAGGACCTGCTGGT GACAACCCCC TGGAGCTGAG 1140 TAGGATTCCT GATGAAAACT GCCAGATTAACAGATATGGC CACTTTCAAG CCACCATCAC 1200 AATTGTAGAG GGAATCTTAG AGGTTAACATCATCCAGATG ACAGACGTCC TGATGCCGGT 1260 GCCATGGCCT GAAAGCTCCC TAATAGACTTTGTCGTGACC TGCCAAGGGA GCATTCCCAC 1320 GGAGGTCTGT ACCATCATTT CTGACCCCACCTGCGAGATC ACCCAGAACA CAGTCTGCAG 1380 CCCTGTGGAT GTGGATGAGA TGTGTCTGCTGACTGTGAGA CGAACCTTCA ATGGGTCTGG 1440 GACGTACTGT GTGAACCTCA CCCTGGGGGATGACACAAGC CTGGCTCTCA CGAGCACCCT 1500 GATTTCTGTT CCTGACAGAG ACCCAGCCTCGCCTTTAAGG ATGGCAAACA GTGCCCTGAT 1560 CTCCGTTGGC TGCTTGGCCA TATTTGTCACTGTGATCTCC CTCTTGGTGT ACAAAAAACA 1620 CAAGGAATAC AACCCAATAG AAAATAGTCCTGGGAATGTG GTCAGAAGCA AAGGCCTGAG 1680 TGTCTTTCTC AACCGTGCAA AAGCCGTGTTCTTCCCGGGA AACCAGGAAA AGGATCCGCT 1740 ACTCAAAAAC CAAGAATTTA AAGGAGTTTCTTAAATTTCG ACCTTGTTTC TGAAGCTCAC 1800 TTTTCAGTGC CATTGATGTG AGATGTGCTGGAGTGGCTAT TAACCTTTTT TTCCTAAAGA 1860 TTATTGTTAA ATAGATATTG TGGTTTGGGGAAGTTGAATT TTTTATAGGT TAAATGTCAT 1920 TTTAGAGATG GGGAGAGGGA TTATACTGCAGGCAGCTTCA GCCATGTTGT GAAACTGATA 1980 AAAGCAACTT AGCAAGGCTT CTTTTCATTATTTTTTATGT TTCACTTATA AAGTCTTAGG 2040 TAACTAGTAG GATAGAAACA CTGTGTCCCGAGAGTAAGGA GAGAAGCTAC TATTGATTAG 2100 AGCCTAACCC AGGTTAACTG CAAGAAGAGGCGGGATACTT TCAGCTTTCC ATGTAACTGT 2160 ATGCATAAAG CCAATGTAGT CCAGTTTCTAAGATCATGTT CCAAGCTAAC TGAATCCCAC 2220 TTCAATACAC ACTCATGAAC TCCTGATGGAACAATAACAG GCCCAAGCCT GTGGTATGAT 2280 GTGCACACTT GCTAGACTCA GAAAAAATACTACTCTCATA AATGGGTGGG AGTATTTTGG 2340 TGACAACCTA CTTTGCTTGG CTGAGTGAAGGAATGATATT CATATATTCA TTTATTCCAT 2400 GGACATTTAG TTAGTGCTTT TTATATACCAGGCATGATGC TGAGTGACAC TCTTGTGTAT 2460 ATTTCCAAAT TTTTGTATAG TCGCTGCACATATTTGAAAT CATATATTAA GACTTTCCAA 2520 AGATGAGGTC CCTGGTTTTT CATGGCAACTTGATCAGTAA GGATTTCACC TCTGTTTGTA 2580 ACTAAAACCA TCTACTATAT GTTAGACATGACATTCTTTT TCTCTCCTTC CTGAAAAATA 2640 AAGTGTGGGA AGAGACAAAA AAAAAAAAA2669 (2) INFORMATION FOR SEQ ID NO: 92: (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 335 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL:NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINALSOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92: AAGGTGAAAG ATGTGTATGTGATAACAGAT CAGATCCCTG TATTCGTGAC CATGTCCCAG 60 AAGAATGACA GGAACTTGTCTGATGAGATC TTCCTCAGAG ACCTCCCCAT CGTCTTCGAT 120 GTCCTCATTC ATGATCCCAGCCACTTCCTC AACGACTCTG CCATTTCCTA CAAGTGGAAC 180 TTTGGGGACA ACACTGGCCTGTTTGTCTCC AACAATCACA CTTTGAATCA CACTTATGTG 240 CTCAATGGAA CCTTCAACCTTAACCTCACC GTGCAAACTG CAGTGCCCGG GCCATGCCCT 300 CCCCCTTCGC CTTCGACTCCGCCTCCACCT TCGTA 335 (2) INFORMATION FOR SEQ ID NO: 93: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 262 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93: AAGGTGAAAGATGTGTATGT GATAACAGAT CAGATCCCTG TATTCGTGAC CATGTCCCAG 60 AAGAATGACAGGAACTTGTC TGATGAGATC TTCCTCAGAG ACCTCCCCAT CGTCTTCGAT 120 GTCCTCATTCATGATCCCAG CCACTTCCTC AACGACTCTG CCATTTCCTA CAAGTGGAAC 180 TTTGGGGACAACACTGGCCT GTTTGTCTCC AACAATCACA CTTTGAATCA CACTTATGTG 240 CTCAATGGAACCTTCAACCT TA 262 (2) INFORMATION FOR SEQ ID NO: 94: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 335 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94: AAGGTGAAAGATGTGTATGT GATAACAGAT CAGATCCCTG TATTCGTGAC CATGTCCCAG 60 AAGAATGACAGGAACTTGTC TGATGAGATC TTCCTCAGAG ACCTCCCCAT CGTCTTCGAT 120 GTCCTCATTCATGATCCCAG CCACTTCCTC AACGACTCTG CCATTTCCTA CAAGTGGAAC 180 TTTGGGGACAACACTGGCCT GTTTGTCTCC AACAATCACA CTTTGAATCA CACTTATGTG 240 CTCAATGGAACCTTCAACCT TAACCTCACC GTGCAAACTG CAGTGCCCGG GCCATGCCCT 300 CCCCCTTCGCCTTCGACTCC GCCTCCACCT TCGTA 335 (2) INFORMATION FOR SEQ ID NO: 95: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 190 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95: TACGAAGGTG GAGGCGGAGT CGAAGGCGAA GGGGGAGGGC ATGGCCCGGG CACTGCAGTT 60TGCACGGTGA GGTTAAGGTT GAAGGTTCCA TTGAGCACAT AAGTGTGATT CAAAGTGTGA 120TTGTTGGAGA CAAACAGGCC AGTGTTGTCC CCAAAGTTCC ACTTGTAGGA AATGGCAGAG 180TCGTTGAGGA 190 (2) INFORMATION FOR SEQ ID NO: 96: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 335 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96: AAGGTGAAAGATGTGTATGT GATAACAGAT CAGATCCCTG TATTCGTGAC CATGTCCCAG 60 AAGAATGACAGGAACTTGTC TGATGAGATC TTCCTCAGAG ACCTCCCCAT CGTCTTCGAT 120 GTCCTCATTCATGATCCCAG CCACTTCCTC AACGACTCTG CCATTTCCTA CAAGTGGAAC 180 TTTGGGGACAACACTGGCCT GTTTGTCTCC AACAATCACA CTTTGAATCA CACTTATGTG 240 CTCAATGGAACCTTCAACCT TAACCTCACC GTGCAAACTG CAGTGCCCGG GCCATGCCCT 300 CCCCCTTCGCCTTCGACTCC GCCTCCACCT TCGTA 335 (2) INFORMATION FOR SEQ ID NO: 97: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 74 amino acids (B) TYPE: aminoacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:N-terminal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97: Arg Arg Trp Arg Arg Ser Arg Arg Arg Arg Gly Arg Ala Trp Gly His 1 510 15 Cys Ser His Gly Val Lys Val Gly Ser His Ser Val Ser Val Val Gly 2025 30 Asp Lys Ala Ser Val Val Lys Val Val Gly Asn Gly Arg Val Val Val 3540 45 Ala Gly Met Asn Asp Asp Asp Gly Val Ser Asp Arg Val Val Gly His 5055 60 Gly His Tyr Arg Asp Cys Tyr His His His 65 70 (2) INFORMATION FORSEQ ID NO: 98: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 71 amino acids(B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 98: Lys Val Lys Asp Val Tyr Val Thr Asp Val ValThr Met Ser Lys Asn 1 5 10 15 Asp Arg Asn Ser Asp Arg Asp Val Asp ValHis Asp Ser His Asn Asp 20 25 30 Ser Ala Ser Tyr Lys Trp Asn Gly Asp AsnThr Gly Val Ser Asn Asn 35 40 45 His Thr Asn His Thr Tyr Val Asn Gly ThrAsn Asn Thr Val Thr Ala 50 55 60 Val Gly Cys Ser Ser Thr Ser 65 70 (2)INFORMATION FOR SEQ ID NO: 99: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:75 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 99: Tyr Gly Gly Gly Gly Val Gly Gly GlyGly His Gly Gly Thr Ala Val 1 5 10 15 Cys Thr Val Arg Arg Lys Val SerThr Val Lys Val Thr Asn Arg Val 20 25 30 Ser Lys His Met Ala Ser Arg LysTrp Gly Ser Met Arg Thr Ser Lys 35 40 45 Thr Met Gly Arg Ser Arg Lys SerSer Asp Lys Ser Trp Asp Met Val 50 55 60 Thr Asn Thr Gly Ser Val Thr TyrThr Ser Thr 65 70 75 (2) INFORMATION FOR SEQ ID NO: 100: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 376 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100: Met CysTyr Tyr Gly Ala Ala Arg Asp Ala Ala Lys Arg His Asp Val 1 5 10 15 GlyAsn Arg Ser Ala Tyr Met Arg His Asn Asn Gly Trp Ser Ser Asp 20 25 30 AsnAsp Trp Asn Lys Tyr Val Trp Lys Arg Gly Asp Met Arg Trp Lys 35 40 45 AsnSer Trp Lys Gly Gly Arg Val Ala Val Thr Ser Asp Ser Ala Val 50 55 60 GlySer Asn Thr Ala Val Asn Arg Cys Lys Asp Ala Asn Gly Asn Val 65 70 75 80Tyr Lys Asn Cys Arg Asn Ala Gly Ser Ala Asp Tyr Val Tyr Asn Trp 85 90 95Thr Ala Trp Ser Asp Ser Asp Gly Asn Gly Thr Gly Ser His His Asn 100 105110 Val Asp Gly Lys His His Gly Trp Arg Arg Trp Asn Tyr Val His Thr 115120 125 Gly Tyr Lys Gly Arg Cys Ser Val Arg Val Ser Val Asn Thr Ala Asn130 135 140 Val Thr Gly Met Val Thr Val Tyr Arg Arg His Gly Arg Ala TyrVal 145 150 155 160 Ala Val Lys Asp Val Tyr Val Val Thr Asp Val Val ThrMet Lys Asn 165 170 175 Asp Arg Asn Ser Ser Asp Thr Lys Asp Met Asp ValHis Asp Ser His 180 185 190 Asn Tyr Ser Thr Asn Tyr Lys Trp Ser Gly AspAsn Thr Gly Val Ser 195 200 205 Thr Asn His Thr Val Asn His Thr Tyr ValAsn Gly Thr Ser Asn Thr 210 215 220 Val Lys Ala Ala Ala Gly Cys Arg SerLys Thr Ser Gly Ala Gly Asp 225 230 235 240 Asn Ser Arg Asp Asn Cys AsnArg Tyr Gly His Ala Thr Thr Val Gly 245 250 255 Val Asn Met Thr Asp ValMet Val Trp Ser Ser Asp Val Val Thr Cys 260 265 270 Gly Ser Thr Val CysThr Ser Asp Thr Cys Thr Asn Thr Val Cys Ser 275 280 285 Val Asp Val AspMet Cys Thr Val Arg Arg Thr Asn Gly Ser Gly Thr 290 295 300 Tyr Cys ValAsn Thr Gly Asp Asp Thr Ser Ala Thr Ser Thr Ser Val 305 310 315 320 AspArg Asp Ala Ser Arg Met Ala Asn Ser Ala Ser Val Gly Cys Ala 325 330 335Val Thr Val Ser Val Tyr Lys Lys His Lys Tyr Asn Asn Ser Gly Asn 340 345350 Val Val Arg Ser Lys Gly Ser Val Asn Arg Ala Lys Ala Val Gly Asn 355360 365 Lys Asp Lys Asn Lys Gly Val Ser 370 375 (2) INFORMATION FOR SEQID NO: 101: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2669 base pairs(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 101: CAGATGCCAG AAGAACACTG TTGCTCTTGG TGGACGGGCCCAGAGGAATT CAGAGTTAAA 60 CCTTGAGTGC CTGCGTCCGT GAGAATTCAG CATGGAATGTCTCTACTATT TCCTGGGATT 120 TCTGCTCCTG GCTGCAAGAT TGCCACTTGA TGCCGCCAAACGATTTCATG ATGTGCTGGG 180 CAATGAAAGA CCTTCTGCTT ACATGAGGGA GCACAATCAATTAAATGGCT GGTCTTCTGA 240 TGAAAATGAC TGGAATGAAA AACTCTACCC AGTGTGGAAGCGGGGAGACA TGAGGTGGAA 300 AAACTCCTGG AAGGGAGGCC GTGTGCAGGC GGTCCTGACCAGTGACTCAC CAGCCCTCGT 360 GGGCTCAAAT ATAACATTTG CGGTGAACCT GATATTCCCTAGATGCCAAA AGGAAGATGC 420 CAATGGCAAC ATAGTCTATG AGAAGAACTG CAGAAATGAGGCTGGTTTAT CTGCTGATCC 480 ATATGTTTAC AACTGGACAG CATGGTCAGA GGACAGTGACGGGGAAAATG GCACCGGCCA 540 AAGCCATCAT AACGTCTTCC CTGATGGGAA ACCTTTTCCTCACCACCCCG GATGGAGAAG 600 ATGGAATTTC ATCTACGTCT TCCACACACT TGGTCAGTATTTCCAGAAAT TGGGACGATG 660 TTCAGTGAGA GTTTCTGTGA ACACAGCCAA TGTGACACTTGGGCCTCAAC TCATGGAAGT 720 GACTGTCTAC AGAAGACATG GACGGGCATA TGTTCCCATCGCACAAGTGA AAGATGTGTA 780 CGTGGTAACA GATCAGATTC CTGTGTTTGT GACTATGTTCCAGAAGAACG ATCGAAATTC 840 ATCCGACGAA ACCTTCCTCA AAGATCTCCC CATTATGTTTGATGTCCTGA TTCATGATCC 900 TAGCCACTTC CTCAATTATT CTACCATTAA CTACAAGTGGAGCTTCGGGG ATAATACTGG 960 CCTGTTTGTT TCCACCAATC ATACTGTGAA TCACACGTATGTGCTCAATG GAACCTTCAG 1020 CCTTAACCTC ACTGTGAAAG CTGCAGCACC AGGACCTTGTCCGCCACCGC CACCACCACC 1080 CAGACCTTCA AAACCCACCC CTTCTTTAGG ACCTGCTGGTGACAACCCCC TGGAGCTGAG 1140 TAGGATTCCT GATGAAAACT GCCAGATTAA CAGATATGGCCACTTTCAAG CCACCATCAC 1200 AATTGTAGAG GGAATCTTAG AGGTTAACAT CATCCAGATGACAGACGTCC TGATGCCGGT 1260 GCCATGGCCT GAAAGCTCCC TAATAGACTT TGTCGTGACCTGCCAAGGGA GCATTCCCAC 1320 GGAGGTCTGT ACCATCATTT CTGACCCCAC CTGCGAGATCACCCAGAACA CAGTCTGCAG 1380 CCCTGTGGAT GTGGATGAGA TGTGTCTGCT GACTGTGAGACGAACCTTCA ATGGGTCTGG 1440 GACGTACTGT GTGAACCTCA CCCTGGGGGA TGACACAAGCCTGGCTCTCA CGAGCACCCT 1500 GATTTCTGTT CCTGACAGAG ACCCAGCCTC GCCTTTAAGGATGGCAAACA GTGCCCTGAT 1560 CTCCGTTGGC TGCTTGGCCA TATTTGTCAC TGTGATCTCCCTCTTGGTGT ACAAAAAACA 1620 CAAGGAATAC AACCCAATAG AAAATAGTCC TGGGAATGTGGTCAGAAGCA AAGGCCTGAG 1680 TGTCTTTCTC AACCGTGCAA AAGCCGTGTT CTTCCCGGGAAACCAGGAAA AGGATCCGCT 1740 ACTCAAAAAC CAAGAATTTA AAGGAGTTTC TTAAATTTCGACCTTGTTTC TGAAGCTCAC 1800 TTTTCAGTGC CATTGATGTG AGATGTGCTG GAGTGGCTATTAACCTTTTT TTCCTAAAGA 1860 TTATTGTTAA ATAGATATTG TGGTTTGGGG AAGTTGAATTTTTTATAGGT TAAATGTCAT 1920 TTTAGAGATG GGGAGAGGGA TTATACTGCA GGCAGCTTCAGCCATGTTGT GAAACTGATA 1980 AAAGCAACTT AGCAAGGCTT CTTTTCATTA TTTTTTATGTTTCACTTATA AAGTCTTAGG 2040 TAACTAGTAG GATAGAAACA CTGTGTCCCG AGAGTAAGGAGAGAAGCTAC TATTGATTAG 2100 AGCCTAACCC AGGTTAACTG CAAGAAGAGG CGGGATACTTTCAGCTTTCC ATGTAACTGT 2160 ATGCATAAAG CCAATGTAGT CCAGTTTCTA AGATCATGTTCCAAGCTAAC TGAATCCCAC 2220 TTCAATACAC ACTCATGAAC TCCTGATGGA ACAATAACAGGCCCAAGCCT GTGGTATGAT 2280 GTGCACACTT GCTAGACTCA GAAAAAATAC TACTCTCATAAATGGGTGGG AGTATTTTGG 2340 TGACAACCTA CTTTGCTTGG CTGAGTGAAG GAATGATATTCATATATTCA TTTATTCCAT 2400 GGACATTTAG TTAGTGCTTT TTATATACCA GGCATGATGCTGAGTGACAC TCTTGTGTAT 2460 ATTTCCAAAT TTTTGTATAG TCGCTGCACA TATTTGAAATCATATATTAA GACTTTCCAA 2520 AGATGAGGTC CCTGGTTTTT CATGGCAACT TGATCAGTAAGGATTTCACC TCTGTTTGTA 2580 ACTAAAACCA TCTACTATAT GTTAGACATG ACATTCTTTTTCTCTCCTTC CTGAAAAATA 2640 AAGTGTGGGA AGAGACAAAA AAAAAAAAA 2669 (2)INFORMATION FOR SEQ ID NO: 102: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 376 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102: Met Cys Tyr Tyr Gly Ala AlaArg Asp Ala Ala Lys Arg His Asp Val 1 5 10 15 Gly Asn Arg Ser Ala TyrMet Arg His Asn Asn Gly Trp Ser Ser Asp 20 25 30 Asn Asp Trp Asn Lys TyrVal Trp Lys Arg Gly Asp Met Arg Trp Lys 35 40 45 Asn Ser Trp Lys Gly GlyArg Val Ala Val Thr Ser Asp Ser Ala Val 50 55 60 Gly Ser Asn Thr Ala ValAsn Arg Cys Lys Asp Ala Asn Gly Asn Val 65 70 75 80 Tyr Lys Asn Cys ArgAsn Ala Gly Ser Ala Asp Tyr Val Tyr Asn Trp 85 90 95 Thr Ala Trp Ser AspSer Asp Gly Asn Gly Thr Gly Ser His His Asn 100 105 110 Val Asp Gly LysHis His Gly Trp Arg Arg Trp Asn Tyr Val His Thr 115 120 125 Gly Tyr LysGly Arg Cys Ser Val Arg Val Ser Val Asn Thr Ala Asn 130 135 140 Val ThrGly Met Val Thr Val Tyr Arg Arg His Gly Arg Ala Tyr Val 145 150 155 160Ala Val Lys Asp Val Tyr Val Val Thr Asp Val Val Thr Met Lys Asn 165 170175 Asp Arg Asn Ser Ser Asp Thr Lys Asp Met Asp Val His Asp Ser His 180185 190 Asn Tyr Ser Thr Asn Tyr Lys Trp Ser Gly Asp Asn Thr Gly Val Ser195 200 205 Thr Asn His Thr Val Asn His Thr Tyr Val Asn Gly Thr Ser AsnThr 210 215 220 Val Lys Ala Ala Ala Gly Cys Arg Ser Lys Thr Ser Gly AlaGly Asp 225 230 235 240 Asn Ser Arg Asp Asn Cys Asn Arg Tyr Gly His AlaThr Thr Val Gly 245 250 255 Val Asn Met Thr Asp Val Met Val Trp Ser SerAsp Val Val Thr Cys 260 265 270 Gly Ser Thr Val Cys Thr Ser Asp Thr CysThr Asn Thr Val Cys Ser 275 280 285 Val Asp Val Asp Met Cys Thr Val ArgArg Thr Asn Gly Ser Gly Thr 290 295 300 Tyr Cys Val Asn Thr Gly Asp AspThr Ser Ala Thr Ser Thr Ser Val 305 310 315 320 Asp Arg Asp Ala Ser ArgMet Ala Asn Ser Ala Ser Val Gly Cys Ala 325 330 335 Val Thr Val Ser ValTyr Lys Lys His Lys Tyr Asn Asn Ser Gly Asn 340 345 350 Val Val Arg SerLys Gly Ser Val Asn Arg Ala Lys Ala Val Gly Asn 355 360 365 Lys Asp LysAsn Lys Gly Val Ser 370 375 (2) INFORMATION FOR SEQ ID NO: 103: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 247 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103: CTGACCAGGA ACCCACTCTT CTGTGCATGT ATGTGAGCTG TGCAGAAGTA TGTGGCTGGG60 AACTGTTGTT CTCTAAGGAT TATTGTAAAA TGTATATCGT GGCTTAGGGA GTGTGGTTAA 120ATAGCATTTT AGAGAAGAAA AAAAAAAAAA AAAAAACTCG AGAGTACTTC TAGAGCGGCC 180GCGGCGCCAT CGATTTTCCA CCCGGGTGGG GTACCAGGTA AGTGTACCCA ATTCGCCTAT 240AGTGAGT 247 (2) INFORMATION FOR SEQ ID NO: 104: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 363 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104: AGGACAAGCCAAGGACACTC TAAGTCTTTG GCCTTCCCTC TGACCAGGAA CCCACTCTTC 60 TGTGCATGTATGTGAGCTGT GCAGAAGTAT GTGGCTGGGA ACTGTTGTTC TCTAAGGATT 120 ATTGTAAAATGTATATCGTG GCTTAGGGAG TGTGGTTAAA TAGCATTTTA GAGAAGACAT 180 GGGAAGACTTAGTGTTTCTT CCCATCTGTA TTGTGGTTTT TACACTGTTC GTGGGGTGGA 240 CACGCTGTGTCTGAAGGGGA GGTGGGGGTC ACTGCTACTT AAGGTCCTAG GTTAACTGGG 300 GGAGATACCACAGATGCTCA GCTTTCCACA TAACATGGGC ATGAACCAGC TAATCACACT 360 GAA 363 (2)INFORMATION FOR SEQ ID NO: 105: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 524 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105: GGATCCTTCT CCTGGTCTCCTCGGAAGAAC GGGGCTTTCG CGTGACTGAG GAGAACACTC 60 AGGCCCTTGC CCTTGACCGTGTTCCTGGGG CAGTTTCCTA TTGGCTTGTA CGCCTTGTGT 120 TTTTTGTACA GCAAGATGGTAACCATGGTG ACAAGCACAG CCAGGCAGCC GATGGAGATC 180 AGGACACCAT TCACTGCTCTCAGAGGGAGT CTGGGTCTTT GCCAGGGATA GAGATCAGGG 240 TGCTGGTGAG GGCCAGGCTTCGATCATCTC CCAGAGTGAA ATTCACACAG TAGGTGCCAG 300 ACCCATTGAA GGCTCTTCTCACAGACAGCA GCACAGCCCA TCCACAGCCA CAGGGCTGCA 360 GACCCGGTTC TGGGCGATCTGGCAGGTGGG GTCGGAGATG ATCGTACAGG CTTCCATGGG 420 GGTGGCCCCT TTGCAGGTCACAGTGAAGTC CATCAGGGAG TTGGCAGGCT GCGGTGTGGG 480 CATGGGGACA TCTGCTATCTGCATGATGCT GACTTCCAGG ATCC 524 (2) INFORMATION FOR SEQ ID NO: 106: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 309 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106: TAGCAGATGT CCCCATGCCC ACACCGCAGC CTGCCAACTC CCTGATGGAC TTCACTGTGA60 CCTGCAAAGG GGCCACCCCC ATGGAAGCCT GTACGATCAT CTCCGACCCC ACCTGCCAGA 120TCGCCCAGAA CCGGGTCTGC AGCCCTGTGG CTGTGGATGG GCTGTGCTGC TGTCTGTGAG 180AAGAGCCTTC AATGGGTCTG GCACCTACTG TGTGAATTTC ACTCTGGGAG ATGATCGAAG 240CCTGGCCCTC ACCAGCACCC TGATCTCTAT CCCTGGCAAA GACCCAGACT CCCTCTGAGA 300GCAGTGAAT 309 (2) INFORMATION FOR SEQ ID NO: 107: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 292 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107: GGATCCTTCTCCTGGTCTCC TCGGAAGAAC GGGGCTTTCG CGTGACTGAG GAGAACACTC 60 AGGCCCTTGCCCTTGACCGT GTTCCTGGGG CAGTTTCCTA TTGGCTTGTA CGCCTTGTGT 120 TTTTTGTACAGCAAGATGGT AACCATGGTG ACAAGCACAG CCAGGCAGCC GATGGAGATC 180 AGGACACCATTCACTGCTCT CAGAGGGAGT CTGGGTCTTT GCCAGGGATA GAGATCAGGG 240 TGCTGGTGAGGGCCAGGCTT CGATCATCTC CCAGAGTGAA ATTCACACAG TA 292 (2) INFORMATION FORSEQ ID NO: 108: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 263 base pairs(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 108: TTTTTTTTTT TTTTTTTTAG ACTGCCTTTT TAATGAGTAGAATATGTACA CACACGCACC 60 ATACACAAAG CCCGGGCCCA TTATAATTTT GTCAGGAGCTCAGGCATGCT CAGTGAGTTG 120 GAAGGCAGAT GAAGCATGCC TTCAGGTGGT GATTAGCTGGGTTCATGCCC ATGTTATCGT 180 GGAAAGCTGA GGCATCTGTG GTATCTCCCC CAGTTAACCTAGGACCTTAA GTAGCAGTGA 240 CCCACCTCCC TTCAGACACA GCG 263 (2) INFORMATIONFOR SEQ ID NO: 109: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 270 basepairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE:NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 109: GGATCCTGGA AGTCAGCATC ATGCAGATAG CAGATGTCCCCATGCCCACA CCGCAGCCTG 60 CCAACTCCCT GATGGACTTC ACTGTGACCT GCAAAGGGGCCACCCCCATG GAAGCCTGTA 120 CGATCATCTC CGACCCCACC TGCCAGATCG CCCAGAACCGGGTCTGCAGC CCTGTGGCTG 180 TGGATGGGCT GTGCTGCTGT CTGTGAGAAG AGCCTTCAATGGGTCTGGCA CCTACTGTGT 240 GAATTTCACT CTGGGAGATG ATCGAAGCCT 270 (2)INFORMATION FOR SEQ ID NO: 110: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 239 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 110: TTTTTTTTTT TTTTTTTTTCTTCTCTAAAA TGCTATTTAA CCACACTCCC TAAGCCACGA 60 TATACATTTT ACAATAATCCTTAGAGAACA ACAGTTCCCA GCCACATACT TCTGCACAGC 120 TCACATACAT GCACAGAAGAGTGGGTTCCT GGTCAGAGGG AAGGCCAAAG ACTTAGAGTG 180 TCCTTGGCTT GTCTGGAGCAATGGATCCTT CTCCTGGTCT CCTCGGAAGA ACGGGCTTT 239 (2) INFORMATION FOR SEQID NO: 111: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 335 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 111: AAACTGCAGT GCCCGGGCCA TGCCCTCCCC CTTCGCCTTCGACTCCGCCT CCACCTTCAA 60 CTCCGCCCTC ACCTCCGCCC TCACCTCTGC CCACATTATCAACACCTAGC CCCTCTTTAA 120 TGCCTACTGG TTACAAATCC ATGGAGCTGA GTGACATTTCCAATGAAAAC TGCCGAATAA 180 ACAGATATGG CTACTTCAGA GCCACCATCA CAATTGTAGAGGGGATCCTG GACGCAGCAT 240 CATGCAGATA GCAGATGTCC CATGCCCACA CCGCAGCCGTCCAACTCCTG ATGGACTTCA 300 CTGTGACCTC AAGGGCACCC ATGGAAGCTG TCAGA 335 (2)INFORMATION FOR SEQ ID NO: 112: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 217 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 112: CCTCAACGAC TCTGCCATTTCCTACAAGTG GAACTTTGGG GACAACACTG GCCTGTTTGT 60 CTCCAACAAT CACACTTTGAATCACACTTA TGTGCTCAAT GGAACCTTCA ACCTTAACCT 120 CACCGTGCAA ACTGCAGTGCCCGGGCCATG CCCTCCCCCT TCGCCTTCGA CTCCGCCTCC 180 ACCTTCAACT CCGCCCTCACCTCCGCCCTC ACCTCTG 217 (2) INFORMATION FOR SEQ ID NO: 113: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 620 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 113: CCTCAACGACTCTGCCATTT CCTACAAGTG GAACTTTGGG GACAACACTG GCCTGTTTGT 60 CTCCAACAATCACACTTTGA ATCACACTTA TGTGCTCAAT GGAACCTTCA ACCTTAACCT 120 CACCGTGCAAACTGCAGTGC CCGGGCCATG CCCTCCCCCT TCGCCTTCGA CTCCGCCTCC 180 ACCTTCAACTCCGCCCTCAC CTCCGCCCTC ACCTCTGCCC ACATTATCAA CACCTAGCCC 240 CTCTTTAATGCCTACTGGTT ACAAATCCAT GGAGCTGAGT GACATTTCCA ATGAAAACTG 300 CCGAATAAACAGATATGGCT ACTTCAGAGC CACCATCACA ATTGTAGAGG GGATCCTGGA 360 AGTCAGCATCATGCAGATAG CAGATGTCCC CATGCCCACA CCGCAGCCTG CCAACTCCCT 420 GATGGACTTCACTGTGACCT GCAAAGGGGC CACCCCCATG GAAGCCTGTA CGATCATCTC 480 CGACCCCACCTGCCAGATCG CCCAGAACCG GGTCTGCAGC CCTGTGGCTG TGGATGGGCT 540 GTGCTGCTGTCTGTGAGAAG AGCCTTCAAT GGGTCTGGCA CCTACTGTGT GAATTTCACT 600 CTGGGAGATGATGCAAGCCT 620 (2) INFORMATION FOR SEQ ID NO: 114: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 354 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 114: GGATCCCCTCTACAATTGTG ATGGTGGCTC TGAAGTAGCC ATATCTGTTT ATTCGGCAGT 60 TTTCATTGGAAATGTCACTC AGCTCCATGG ATTTGTAACC AGTAGGCATT AAAGAGGGGC 120 TAGGTGTTGATAATGTGGGC AGAGGTGAGG GCGGAGGTGA GGGCGGAGTT GAAGGTGGAG 180 GCGGAGTCGAAGGCGAAGGG GGAGGGCATG GCCCGGGCAC TGCAGTTTGC ACGGTGAGGT 240 TAAGGTTGAAGGTTCCATTG AGCACATAAG TGTGATTCAA AGTGTGATTG TTGGAGACAA 300 ACAGGCCAGTGTTGTCCCAA AGTTCCACTT GTAGGAATGG CAGAGTCGTT GAGG 354 (2) INFORMATION FORSEQ ID NO: 115: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 473 base pairs(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 115: CCTCAACGAC TCTGCCATTT CCTACAAGTG GAACTTTGGGGACAACACTG GCCTGTTTGT 60 CTCCAACAAT CACACTTTGA ATCACACTTA TGTGCTCAATGGAACCTTCA ACCTTAACCT 120 CACCGTGCAA ACTGCAGTGC CCGGGCCATG CCCTCCCCCTTCGCCTTCGA CTCCGCCTCC 180 ACCTTCAACT CCGCCCTCAC CTCCGCCCTC ACCTCTGCCCACATTATCAA CACCTAGCCC 240 CTCTTTAATG CCTACTGGTT ACAAATCCAT GGAGCTGAGTGACATTTCCA ATGAAAACTG 300 CCGAATAAAC AGATATGGCT ACTTCAGAGC CACCATCACAATTGTAGAGG GGATCCTGGA 360 AGTCAGCATC ATGCAGATAG CAGATGTCCC CATGCCCACACCGCAGCCTG CCAACTCCCT 420 GATGGACTTC ACTGTGACCT GCAAAGGGGC CACCCCCATGGAAGCCTGTA CGA 473 (2) INFORMATION FOR SEQ ID NO: 116: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 223 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 116: GAAGGTGGAGGCGGAGTCGA AGGCGAAGGG GGAGGGCATG GCCCGGGCAC TGCAGTTTGC 60 ACGGTGAGGTTAAGGTTGAA GGTTCCATTG AGCACATAAG TGTGATTCAA AGTGTGATTG 120 TTGGAGACAAACAGGCCAGT GTTGTCCCCA AAGTTCCACT TGTAGGAAAT GGCAGAGTCG 180 TTGAGGAAGTGGCTGGGATC ATGAATGAGG ACATCGAAGA CGA 223 (2) INFORMATION FOR SEQ ID NO:117: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 247 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:117: GAATTCGCAC GAGGGGAGTC AGAGTCAAGC CCTGACTGGT TGCAGGCGCT CGGAGTCAGC60 ATGGAAAGTC TCTGCGGGGT CCTGGGATTT CTGCTGCTGG CTGCAGGACT GCCTCTCCAG 120GCTGCCAAGC GATTTCGTGA TGTGCTGGGC CATGAACAGT ATCCCGATCA CATGAGAGAG 180CACAACCAAT TACGTGGCTG GTCTTCGGAT GAAAATGAAT GGGTTCCAAT ATCACTTTTG 240TGGTGAA 247 (2) INFORMATION FOR SEQ ID NO: 118: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 240 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 118: GAATTCGGCACGAGGAAGGA GGCCGTGTGC AGGCAGTCCT GACCAGTGAC TCACCGGCTC 60 TGGTGGGTTCCAATATCACT TTTGTGGTGA ACCTGGTGTT CCCCAGATGC CAGAAGGAAG 120 ATGCTAATGGCAATATCGTC TATGAGAAGA ACTGCAGGAA TGATTTGGGA CTGACATCTG 180 ACCTGCATGTCTACAACTGG ACTGCAGGGG CAGATGATGG TGACTGGGAA GATGGCACCT 240 (2)INFORMATION FOR SEQ ID NO: 119: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 260 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 119: GAAGGTGGAG GCGGAGTCGAAGGCGAAGGG GGAGGGCATG GCCCGGGCAC TGCAGTTTGC 60 ACGGTGAGGT TAAGGTTGAAGGTTCCATTG AGCACATAAG TGTGATTCAA AGTGTGATTG 120 TTGGAGACAA ACAGGCCAGTGTTGTCCCCA AAGTTCCACT TGTAGGAAAT GGCAGAGTCG 180 TTGAGGAAGT GGCTGGGATCATGAATGAGG ACATCGAAGA CGATGGGGAG GTCTCTGAGG 240 AAGATCTCAT CAGACAAGTT260 (2) INFORMATION FOR SEQ ID NO: 120: (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 231 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL:NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINALSOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 120: GAATTCGGCA CGAGGTCAAGCCCTGACTGG TTGCAGGCGC TCGGAGTCAG CATGGAAAGT 60 CTCTGCGGGG TCCTGGGATTTCTGCTGCTG GCTGCAGGAC TGCCTCTCCA GGCTGCCAAG 120 CGATTTCGTG ATGTGCTGGGCCATGAACAG TATCCCGATC ACATGAGAGA GCACAACCAA 180 TTACGTGGCT GGTCTTCGGATGAAAATGAA TGGATGAACA CCTTGTATCC A 231 (2) INFORMATION FOR SEQ ID NO:121: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 286 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:121: AAGGGGGAGG GCATGGCCCG GGCACTGCAG TTTGCACGGT GAGGTTAAGG TTGAAGGTTC60 CATTGAGCAC ATAAGTGTGA TTCAAAGTGT GATTGTTGGA GACAAACAGG CCAGTGTTGT 120CCCCAAAGTT CCACTTGTAG GAAATGGCAG AGTCGTTGAG GAAGTGGCTG GGATCATGAA 180TGAGGACATC GAAGACGATG GGGAGGTCTC TGAGGAAGAT CTCATCAGAC AAGTTCCTGT 240CATTCTTCTG GGACATGGTC ACGAATACAG GGATCTGATC TGTTAT 286 (2) INFORMATIONFOR SEQ ID NO: 122: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 224 basepairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE:NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 122: GAATTCGGCA CGAGCCGACA CTGTGACTCC TGGTGGATGGGACTGGGGAG TCAGAGTCAA 60 GCCCTGACTG GTTGCAGGCG CTCGGAGTCA GCATGGAAAGTCTCTGCGGG GTCCTGGGAT 120 TTCTGCTGCT GGCTGCAGGA CTGCCTCTCC AGGCTGCCAAGCGATTTCGT GATGTGCTGG 180 GCCATGAACA GTATCCCGAT CACATGAGAG AGCACAACCAATTA 224 (2) INFORMATION FOR SEQ ID NO: 123: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 335 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 123: AAGGTGAAAGATGTGTATGT GATAACAGAT CAGATCCCTG TATTCGTGAC CATGTCCCAG 60 AAGAATGACAGGAACTTGTC TGATGAGATC TTCCTCAGAG ACCTCCCCAT CGTCTTCGAT 120 GTCCTCATTCATGATCCCAG CCACTTCCTC AACGACTCTG CCATTTCCTA CAAGTGGAAC 180 TTTGGGGACAACACTGGCCT GTTTGTCTCC AACAATCACA CTTTGAATCA CACTTATGTG 240 CTCAATGGAACCTTCAACCT TAACCTCACC GTGCAAACTG CAGTGCCCGG GCCATGCCCT 300 CCCCCTTCGCCTTCGACTCC GCCTCCACCT TCGTA 335 (2) INFORMATION FOR SEQ ID NO: 124: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 266 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:124: TACCATCGGA GAAAGAAGAC CAAGCAAGGC TCAGGCAGCC ACCGCCTGCT TCGCACTGAG60 CCTCCTGACT CAGACTCAGA GTCCAGCACA GACGAAGAGG AATTTGGAGA ATTGGAAATC 120GCTCTCGTTT TGTCAAGGGA GACTATCCCG ATGCTGCAAG ATCTGCTGTC CCTCTGGCCT 180TTGTCATCCT CGCGCCTGCG TTGTGGCCTC TGTGGGCTTG GTGTGGAGCA AATGGCTCTC 240AAGGAGGACT GAGTCTCAAG GAAATT 266 (2) INFORMATION FOR SEQ ID NO: 125: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 300 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:125: AGCTAAGGTC AGGAGGTGTC TGAAGAATTG GCTGATGCAT GGCAGGGATG TTGTTGACCT60 GCTTTTAGAA CAATACTTCC ATTTAATTAT AGCATATCTT ATGTGTGTAT TAAAGCAGAG 120CCGATCTGGT GGGGCTCATT AAGTAAATGT ACTTACTGCA AAAGGTTCAA CTGGTGACCC 180CAGTTTTCCC CAGAAGCAAT ATGATAGGAC AGAGGCGACT CCTGCAAGTT GTCTCAGACT 240TCACACATAC ATTGTGACAT TCTCTGAGCA TGTGCACTGT ACATGATATG ACACTATCAA 300(2) INFORMATION FOR SEQ ID NO: 126: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 312 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 126: AGCTAAGGTC CACTACCTTGTGAAGATGTA TAAACACCTG AAATGTAGAA GCGATCCGTA 60 TGTCAAGATC GAGGGGAAGGACGCTGACGA CTGGCTGTGT GTGGACTTTG GGAGTATGGT 120 GATCCATTTG ATGCTTCCAGAAACCAGAGA AACCTATGAA TTAGAGAAAC TATGGACTCT 180 ACGTTCTTTT GATGACCTTAGCTAAGCCGA ATCAGCACAC TGGCGGCGTT ACTAGTGGAT 240 CGAGCTCGTA CAGCTGATGCATAGCTTGAG TATCTATAGG TTACTAATAG CTGGCTATCA 300 TGTCAAGCGT TC 312 (2)INFORMATION FOR SEQ ID NO: 127: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 281 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 127: GCTGAGCTGC AGAGAGTAGCACATCCTTGC TAATTCAATA ACTACCAGTT TTTATTGGTG 60 AAACATGAAT CCAGATGGTATGGTTGCTCT CCTGGACTAC CGTGAAGATG GTGTGACTCC 120 ATTCATGATT TTCTTTAAGGATGGCTTAGA GATGGAGAAA TGTTAACAAA TTGGATCTAT 180 CACCTGTCAC CATAATTGGCTGCTGCTTAC CATCCATACA ACACCAGGAC TTAGGACAAA 240 TGGGACTGAT GTCATCTTGAGCTTTTATTT TGACCTTAGC T 281 (2) INFORMATION FOR SEQ ID NO: 128: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 295 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:128: AGCTAAGGTC AGAGCCAATA GTATCATGAG AACTGAAGAA GTAATAAAGC AACTTCTCCA60 GAAATTTAAG ATTGAGAATA GCCCTCGGGA TTTCGCTCTT TACATTATTT TTGGGACAGG 120AGAGCAGAGA AAGCTAAAGA AGACCGATGT CCACTGCTGC AGAGGTTACT ACAAGGACCA 180TCCAAAAGCA ATGCTCGGAT CTCTCATGGA TAAAGATGCA GAAGAATCAC GAGAGATGTG 240GCTCGTACAT TATTTCACTT TCTTCTGATC ATACTCAAGA TAGATGAGAG AGAAT 295 (2)INFORMATION FOR SEQ ID NO: 129: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 240 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 129: TTGACTTCTG AGTCTAACACAGACACTGCA AGGGTTAATT TTCCAAGAGG TGGTTGTTGT 60 TGACGATAAA TTCATTAAGAATTTTTAAAA ATTTAGTTAG ATTTACCAAA GTCACTGGAG 120 ACAAATTCAG AAGGCATATATACCTGCCAG TTTTGTGGAC TACATTAATA GGGAGGCTTT 180 TATGTTTGAT GTAATTCTTACAGTTCTAAG AATTAAGTTC CATTGCATGA GACCTTAGCT 240 (2) INFORMATION FOR SEQID NO: 130: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 196 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 130: AAGGTGAATC CCCGACGGCT CTGGGCCCGA GGAGAAGCGTCGCCGTGGCA AATTGGCACT 60 GCAGGAGAAG CCCTCCACAG GTACTTGGAA AAACTGGTCTCTGAGGCCAA GGCCAGCTCC 120 GAGACATTCA GGACTTCTGG ATCAGCCTCC AGGGACACTGTGCAGTGAGA AGATGGCCAT 180 GAGTCCTGCC AGTGAG 196 (2) INFORMATION FOR SEQID NO: 131: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 187 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 131: AATTTTTTTT TTCGACGGCC CAACGGGGGC TTGGTGGATGGAAATATGGT TTTGTGAGTT 60 ATTGCACTAC CTGGAATATC TATGCCTCTT ATTTGCGTGTACTGTTGCTG CTGATCGTTT 120 GGTGCTGTGT GAGTGAACCT ATGGCTTAGA AAAACGACTTTGTCTTAAAC TGAGTGGGTG 180 TTCAGGG 187 (2) INFORMATION FOR SEQ ID NO:132: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 197 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:132: CACCTGATTT AAAGGAAAAG CATTCTGACG TAAGAAGCTG AAAGGCGGCC CTTGCGTGCT60 TTGAACTTTC TTATACAGCA CAGTCATCTG AAGCTTCCTG TGTGACCAAG ACAAGAACGC 120GTGCACAAGA CTGAGAAACA GCAAGAAACA ACCCGGCATT CTACTTTCTC AACACTATCA 180TACTTTAAAC CTTTCAC 197 (2) INFORMATION FOR SEQ ID NO: 133: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 200 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 133: CTAGCTTACGCTAGTCCCCC ATGCATAAAG ACTGATCGCT TTTCCTTAGA AAGGTGAGAG 60 GGTTAGGACAAGGCCGTGTG GTAACAACAC CCGCAGCTCG AAAAACCAAT GGCTTGTTAA 120 CGTGTCAGTGAGGCACTGTA CGGACGTCCA TAGTCCACAT CTTCAAATTC CCGCAGAAGG 180 CTTCCTATTCTTAAACTCTA 200 (2) INFORMATION FOR SEQ ID NO: 134: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 300 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 134: CTACATTTCTGTATCCATTC CTCTGTTGAA GGCTCTGGTT CTTTCCAGCT TCTGGCTATT 60 ATAAATAAGGCTGCTATAAA CACAGTGGAG GCATGTGTCC TTGTTATATT TTGGAGCATC 120 TTTTGGGTATATGCCCAGAA GTGCTATAGC TGGTTCCTCA GGTAGTACTA TGTCGAATTT 180 TCTGAGGAACTGCCAGACTG ATTTCCAGAG TGGTTGTACC AGCTTGCAAT CCCACCAGCA 240 ATAGAGGAGTGTTCCTCTTT CTCTATATTC TTGCCAACAT CTGCTGTCAC CTGAGTGTTT 300 (2)INFORMATION FOR SEQ ID NO: 135: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 243 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 135: TGGTAAAGGG GGAATGATGTCGAGGCCATC CTGGGCTGTA GAGCCAGGCC CTGGCTTGGG 60 GAGTGGGCAT TGTTAACTTGTTGCTGACTT TGTGTTGACC CCTGCATCAG CAACTATTTC 120 CTTAAATCCA GGATACAACTTGTTAAGTGT GACAGCTTTC CTTTACACAC CATTTTTGTG 180 GGTGTATATA TATATTTGACTTGGGGAGAA TTATTTTTTA CAAAAATACA AAATAGCTTT 240 TAA 243 (2) INFORMATIONFOR SEQ ID NO: 136: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 270 basepairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE:NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 136: AGCTAAGGTC CGGACTCTAT GGCATGACCC CAAAAACATTGGCTGGAAAG ATTACACTGC 60 CTACAGGTGG CACCTGATTC ACAGGCCTAA GACAGGCTACATGAGAGTCT TAGTGCATGA 120 AGGAAAGCAA GTCATGGCTG ACTCAGGACC AATTTATGACCAAACCTACG CTGGTGGACG 180 GCTGGGCTGT TTGTCTTCTC CAAGAGATGG TCTATTCTCGGACCTCAAGT ATGAGTGCAG 240 AGATGCTAGA GAGCAGGCTC AGTCTCAGCA 270 (2)INFORMATION FOR SEQ ID NO: 137: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 260 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 137: TGACCTACGT GTAGTTGGTGTGCTTGTTGT CGAAGATGAG GGCCTCCTGG ATGAGCTGGT 60 GCTGCTGCTC CAGCAGGTCCAGGCTGGGCT TGTAGTCCAC GAGTCTGCGC TCGTACTGCT 120 TCAGGTGGCT CAGCTGGTCTTCCAGAGTCC CGTTCATCTC AATGGAGATG CGCCCGATCT 180 CCTCCATCTT AGTCTGGATCCACGGCCCCA CCATATTGGC TTGGCTGGCG AACTGTCGGC 240 GAAGGCTGCA TTGGATTGCT260 (2) INFORMATION FOR SEQ ID NO: 138: (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 187 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL:NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINALSOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138: AATTTTTTTT TTCGACGGCCCAACGGGGGC TTGGTGGATG GAAATATGGT TTTGTGAGTT 60 ATTGCACTAC CTGGAATATCTATGCCTCTT ATTTGCGTGT ACTGTTGCTG CTGATCGTTT 120 GGTGCTGTGT GAGTGAACCTATGGCTTAGA AAAACGACTT TGTCTTAAAC TGAGTGGGTG 180 TTCAGGG 187 (2)INFORMATION FOR SEQ ID NO: 139: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 197 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 139: CACCTGATTT AAAGGAAAAGCATTCTGACG TAAGAAGCTG AAAGGCGGCC CTTGCGTGCT 60 TTGAACTTTC TTATACAGCACAGTCATCTG AAGCTTCCTG TGTGACCAAG ACAAGAACGC 120 GTGCACAAGA CTGAGAAACAGCAAGAAACA ACCCGGCATT CTACTTTCTC AACACTATCA 180 TACTTTAAAC CTTTCAC 197(2) INFORMATION FOR SEQ ID NO: 140: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 200 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 140: CTAGCTTACG CTAGTCCCCCATGCATAAAG ACTGATCGCT TTTCCTTAGA AAGGTGAGAG 60 GGTTAGGACA AGGCCGTGTGGTAACAACAC CCGCAGCTCG AAAAACCAAT GGCTTGTTAA 120 CGTGTCAGTG AGGCACTGTACGGACGTCCA TAGTCCACAT CTTCAAATTC CCGCAGAAGG 180 CTTCCTATTC TTAAACTCTA200 (2) INFORMATION FOR SEQ ID NO: 141: (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 300 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL:NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINALSOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 141: CTACATTTCT GTATCCATTCCTCTGTTGAA GGCTCTGGTT CTTTCCAGCT TCTGGCTATT 60 ATAAATAAGG CTGCTATAAACACAGTGGAG GCATGTGTCC TTGTTATATT TTGGAGCATC 120 TTTTGGGTAT ATGCCCAGAAGTGCTATAGC TGGTTCCTCA GGTAGTACTA TGTCGAATTT 180 TCTGAGGAAC TGCCAGACTGATTTCCAGAG TGGTTGTACC AGCTTGCAAT CCCACCAGCA 240 ATAGAGGAGT GTTCCTCTTTCTCTATATTC TTGCCAACAT CTGCTGTCAC CTGAGTGTTT 300 (2) INFORMATION FOR SEQID NO: 142: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 243 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 142: TGGTAAAGGG GGAATGATGT CGAGGCCATC CTGGGCTGTAGAGCCAGGCC CTGGCTTGGG 60 GAGTGGGCAT TGTTAACTTG TTGCTGACTT TGTGTTGACCCCTGCATCAG CAACTATTTC 120 CTTAAATCCA GGATACAACT TGTTAAGTGT GACAGCTTTCCTTTACACAC CATTTTTGTG 180 GGTGTATATA TATATTTGAC TTGGGGAGAA TTATTTTTTACAAAAATACA AAATAGCTTT 240 TAA 243 (2) INFORMATION FOR SEQ ID NO: 143:(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 270 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:143: AGCTAAGGTC CGGACTCTAT GGCATGACCC CAAAAACATT GGCTGGAAAG ATTACACTGC60 CTACAGGTGG CACCTGATTC ACAGGCCTAA GACAGGCTAC ATGAGAGTCT TAGTGCATGA 120AGGAAAGCAA GTCATGGCTG ACTCAGGACC AATTTATGAC CAAACCTACG CTGGTGGACG 180GCTGGGCTGT TTGTCTTCTC CAAGAGATGG TCTATTCTCG GACCTCAAGT ATGAGTGCAG 240AGATGCTAGA GAGCAGGCTC AGTCTCAGCA 270 (2) INFORMATION FOR SEQ ID NO: 144:(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 260 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:144: TGACCTACGT GTAGTTGGTG TGCTTGTTGT CGAAGATGAG GGCCTCCTGG ATGAGCTGGT60 GCTGCTGCTC CAGCAGGTCC AGGCTGGGCT TGTAGTCCAC GAGTCTGCGC TCGTACTGCT 120TCAGGTGGCT CAGCTGGTCT TCCAGAGTCC CGTTCATCTC AATGGAGATG CGCCCGATCT 180CCTCCATCTT AGTCTGGATC CACGGCCCCA CCATATTGGC TTGGCTGGCG AACTGTCGGC 240GAAGGCTGCA TTGGATTGCT 260 (2) INFORMATION FOR SEQ ID NO: 145: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 255 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:145: TGACCATCGA TAAGTTTAAT AACTACAGAC TTTTCCCAAG ACTACAAAAG CTTCTTGAAA60 GTGACTACTT TAGATATTAC AAGGTGAACT TGAAGAAGCC TTGTCCTTTC TGGAATGACA 120TCAACCAGTG TGGAAGAAGA GACTGTGCCG TCAAACCCTG CCATTCTGAT GAAGTTCCTG 180ATGGAATTAA GTCTGCCGAG CTACAAGTAT TCTGAGGAAG CCCAACCGCA TTGAAGAATG 240TGAGCAAGCT GAGCG 255 (2) INFORMATION FOR SEQ ID NO: 146: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 236 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 146: AACTCTGTGAACCGTGCCTT TCTCTGTGGA GGTGGAGGTG TCGGTTGAAG ACAAGCGAGG 60 TCCTCCAAGGGGCTGTGTCT TATGTTGCCA TCTCCCCTTG TAGCTTGGCT GCCCACCCTC 120 CAGACTGTGCGCCATGGCTC CAAGGCTGTG ACCCGCCACT GGAGTCATGC ACTTCCAGCG 180 GCAGAAGCTGATGCTATAAC TGAGTATATT CCTCCAAACC TGCCATCAAC CCGAGA 236 (2) INFORMATIONFOR SEQ ID NO: 147: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 291 basepairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE:NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 147: ACTTCTCCAG AGAATTTAAG ATTGAGAATA GCCCTCGGGATTTCGCTCTT TACATTATTT 60 TTGGGACAGG AGAGCAGAGA AAGCTAAAGA AGACCGATGTCCCACTGCTG CAGAGGTTAC 120 TACAAGGACC ATCCAAAAGC AATGCTCGGA TCTTCCTCATGGATAAAGAT GCAGAAGAAA 180 TCAGCAGAGA TGTGGCTCCG TACATTAATT TCACTTTTCTTTCTTGGATC CATCCTTCAA 240 GATTAGATGA AGAAGAGAAA TGGAGATTGA GAGAATATGCAATCATACCG A 291 (2) INFORMATION FOR SEQ ID NO: 148: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 255 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 148: AGGGTTACTTCAGGCTAAGG CAATAGAAAT CCATTTTAAG ATGGTGTGCT AAAGGCTTGA 60 TGGATGTTCATCGTCTGTCT AAAGGAGAAT GAAGTCATCA ACAGGATGTC AGGGGAAAGT 120 GAGATCATCGCAGAAAGTAT CAACTTAGCA CAAACACACA GGCATAGCTC CTGCAAGAGG 180 TGAATGCTGTCCCCAAATAC CTGAGGAACT ATCCCTTTGG GCAAGAAAAT AGACAAGTCC 240 ATGAAGTCTGGGTGA 255 (2) INFORMATION FOR SEQ ID NO: 149: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 284 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 149: GACCAGGTACACTTGAGCAA AGCACCCAGT ATTTAATTCC TTACAGAAAG GAGAGGAAAG 60 GTCTGCAGTTGGACTGATGG TATGCTAACA CCGCAAATGA CTGTCATTTG ATCTCAGAAG 120 TTCAGGATTGATTGCTATGT TTTAGCTCTA ATTGTGAGAA ACAGTAGTCA TTTTAGTCTT 180 AAATTTTGCCCTCAGGAAAT TCAGGGAGAC TGAGCCTTCC TTCCCCCACC TTCGTAAAGC 240 CGAATTCCAGCACACGGCGG CCGTTACTAG TGGATCCGAG CTCG 284 (2) INFORMATION FOR SEQ ID NO:150: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 335 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:150: TACAAGGTGG GATGGCAGGA ACTGAAGGCT TCTGTAAATC CAGTTTTGGC TCTCTCTCTG60 GTCTTTCTTT CTCTTCTGTT CTGTTTGGAA GGGTTTCTGG TCTTTCAGGA GGTATTTTTT 120TAATTTCATG TTTTCTCTCT GTGGTACCTG CCCCTTGTTT GACGACAGGA GCTGATGGAG 180GTGGCGGTTT CTTGGGTCTA TTCCCTTCCT TGTCAAAGTC CGATGGAAGT AACTTCACGA 240AGTTGTCAGG AAACACGCCT CGTCTGCCAT TGAGTTCTCC TTCCCACCAG CCTACGCGAT 300GCAGTCTTAT TGATGAGAGT CACTATATCT CCTTA 335 (2) INFORMATION FOR SEQ IDNO: 151: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 254 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 151: TCACCCATGA CTTCTATGGA CTTGTCTATT TTCTTGCCCAAAGGGATAGT TCCTCAGGTA 60 TTTGGGGACA GCATTCACCT CTTGCAGGAG CTATGCCTGTGTGTTTGTGC TAAGTTGATA 120 CTTTCTGCGA TGATCTCACT TTCCCCTGAC ATCCTGTTGATGACTTCATT CTCCTTTAGA 180 CAGACGATGA ACATCCATCA GGCCTTTATG CACACCATCTTAAAATGGAT TTCTATTGCC 240 TTAGCCTGAA GTCC 254 (2) INFORMATION FOR SEQ IDNO: 152: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 241 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 152: CCCATAGAGA TAGGTTTGCT CCAGAACCTG CAGCATTTGCACATCACAGG GAACAAGGTG 60 GACATTCTGC CAAAACAGTT GTTTAAGTGC GTGAAGTTGAGGACTTTGAA CCTGGGGCAG 120 AACTGTATCG CCTCCCTGCC TGAGAAAATC AGTCAGCTCACCCAGCTCAC TCAGCTGGAG 180 CTGAAGGGCA ACTGCCTAGA CCGCCTGCCA GCCCAGCTGGCAGTGTCGAT GCTCAAGAAG 240 A 241 (2) INFORMATION FOR SEQ ID NO: 153: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 256 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:153: CAATAATCCA GGTAAAATAG AGTAAAATAG TCTGCTAGCA GCAAGTTCCT ACCATACTTT60 CAACAACACT CACGAGATAC GGAATGATTA CAGCATTAAG AATATTTCAG AAATGACAGG 120TAGGTGTGGT GGACAGGTGG CTCACATTCA AGACTCAAGT CTACTTAAAA AAGAAAATCT 180CACTAGCACT AGATTCTAGC TCCTTTGTTT CCCCCTTTCT TTTGGTTTCA AAGGCGTTTC 240TACAACCCAT AAGAGG 256 (2) INFORMATION FOR SEQ ID NO: 154: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 404 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 154: GCCAAGCTATTATGACACTA TAGATACTCA ACGTATCGAT CAACGTTGGT ACCGAGCTCG 60 GATCCACTAGTAACGGCCGC CAGTGTGCTG GAATTCGGCT TGGATTGGTC AGAGCAGTGT 120 GCAATATGATCCAACTAAGT CTCCTCCCTT GGCCCCTCCC CAAAATGTTT GCAGTGTTAT 180 TTTTGTGGGTTTTTTTTTAA CACCCTGACA CCTGTTGTGG ACATTGTCAA CCTTTGTAAG 240 AAAACCCAAATAAAAATTGA AAAATAAAAT AAAAAGAAAC CCATGAACAT TCGCACCACT 300 TGTGGCTTCTGACTATCTTC CACAGAGGGA AGTTTAAAAC CCAAACTTCC AAAGGTTTGA 360 ACTACCTCAAGACACTTTCG CAGTGGAGTC GTAGACCAAT CCCA 404 (2) INFORMATION FOR SEQ ID NO:155: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 167 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:155: TAAATAAATT AAAAAACTAT TAAACCTAAA AACGTCCACC AAACCCTAAA ACCATTAAAC60 AACCAACAAA CCCACTAACA ATTAAACCTA AACCTCCATA AATAGGTGAA GGCTTTAATG 120CTAACCCAAG ACAACCAACC AAAAATAATG AACTTAAAAC AAAAATA 167 (2) INFORMATIONFOR SEQ ID NO: 156: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 212 basepairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY:linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE:NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 156: GGTAAAGGGG ACCTGGAGAA CGCCTTCCTG AACCTGGTCCAGTGCATCCA GAACAAGCCC 60 CTGTACTTCG CTGACCGGCT GTACGACTCC ATGAAGGGCAAGGGGACTCG AGACAAGGTC 120 TGATTAGAAT CATGGTCTCT CGCAGTGAAG TGGACATGCTGAAAATCAGA TCTGAATTCA 180 AGAGGAATAT GGCAAGTCCT GTACTACTAC AT 212 (2)INFORMATION FOR SEQ ID NO: 157: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 214 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 157: AGAGCAGCAG GCCAGCTGTACTTGGTTTGG CAAGAAAAAG AAGCAGTACA AAGATAAATA 60 TTTGGCAAAG CACAACGCAGTGTTTGATCA ATTAGATCTT GTCACATATG AAGAAGTAGT 120 CAAACTGCCA GCATTCAAAAGGAAAACATT AGTCTTATTA GGTGCACATG GTGTTGGAAG 180 AAGACACATA AAAAATACCCTCATCACAAA GCAC 214 (2) INFORMATION FOR SEQ ID NO: 158: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 342 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 158: TCGGTCATAGTAGTAAGGGA AATCTCCCAG GTAAGATGAA TACTGCGGTA GGACGAACAA 60 TCCTCCAGGATGTTTGTTCC ATATTAAACT GTTACGTGAT ATGTGCTTGA ATATTCTGTC 120 CTGAATAATCTCTAGTGTAG TTAATACAAT CTTCTCAACT GAAGAAAAAT AAGCCTCCCA 180 CAAGAACTGTGTCTGCTGTC TAAGTGCTAG GATTTTATCC TGATGAATAG ACCTGATTGT 240 AGAAGGAATCTGTAATAGCA ATCTCTCATC GCCTATGACC GAAAGCCGAA TTCTGCAGAT 300 ATCCATCACACTGGCCGGCC GCTCGAGCAT CGATCTAGAG GG 342 (2) INFORMATION FOR SEQ ID NO:159: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 303 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:159: CTGCTTGATG ACAAAGGGTG TAGTCTTCAT CTTTTCCTGG ATTATTTTGG AAGTGACAGG60 TGGAAATTCC ATCGTCACGT TTATGTGGTC TGTAAAGCCA ACGATCTCAA ATTCTGGCGG 120CTCAAGAGGA GCGTTTGCAG GCACGATGTA GTCTGAGCAG CGGCACACGG TCAAGTCCCC 180TCTGTGCACT ATGACGATGG CGACGACGTA GCTCTCCATG CCCTCCAACC ACTTATCTGT 240CACGTCACAT GATGACTTCG TGGTATCTGA ACAGTTCTTA ACCTTCGTCA GATTTTCGTC 300TTT 303 (2) INFORMATION FOR SEQ ID NO: 160: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 345 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 160: AAATCGTTGCTTCAGAAAGA CTCAATAACA CTTACTTGTG CCTGGCTGTG CTGACAGTAC 60 ATTCTGTGTCATTTTCCTTC ATGGGCGGAA CAGTCCACAG AGCTCACCAA CAAGTACTCC 120 AAAACTGAGCAAGAGTTTAA GCTTCGAGAT GCAACCAGAT GAGCTTCTAG AAAAGCCCAT 180 GTCTCCCATGCAGTACGCAC GGTCTGGACT AGGGACAGCA GAGATGAATG GCAAACTCAT 240 AGCTGCAGGTGGTTATAACA GAGAGGAATG TCTTCGAACA GTTGAATGCT ATGATCCACA 300 TACAGATCACTGGTCCTTCC TTGCTCCCAT GAGAACATCA AGCAG 345 (2) INFORMATION FOR SEQ IDNO: 161: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 315 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 161: CTTTCCGAAG AGCACACCCT CCTCTCAATG AGCTTGTGAGGTCTCTTTCT TCTCTTCCTT 60 CCAACGTGGT GCTAGCTCCA GGCGAGCGAC GTGAGAGTGCCACCTGAGAC AGACACCTTG 120 GTCTCAGTTA GAAGGAAGAT GCAGGTCTAA GAGGAATCCCCGCAGGTCTG TCTGAGCTGT 180 GATCAAGAAT ATTCCGCAAT GTGCCTTTTC TGAGATCGTGTTAGCTCCAA AGCTTTTTCC 240 TATCGCAGAG TGTTCAGTTT GTGTTTGTTT GTTTTTGTTTTGTTTTGTTT TTCCCTTGGC 300 GGATTTCCCG TGTGT 315 (2) INFORMATION FOR SEQID NO: 162: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 243 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 162: CCTATTGAAC GGTCTTGCAA TGACGAGCAT TCAGATGCTTAAGGAAAGCA TTGCTGCTAC 60 AAATATTTCT ATTTTTAGAA AGGGTTTTTA TGGACCAATGCCCCAGTTGT CAGTCAAAGC 120 CGTTGGTGTT TTCATTGTTT AAAATGTCAC CTATAAAACGGGCATTATTT ATGTTTTTTT 180 TCCCTTTGTT CATATTCTTT TGCATTCCTG ATTATTGTATGTATCGTGTA AAGGAAGTCT 240 GTA 243 (2) INFORMATION FOR SEQ ID NO: 163:(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 243 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:163: CCTATTGAAC GGTCTTGCAA TGACGAGCAT TCAGATGCTT AAGGAAAGCA TTGCTGCTAC60 AAATATTTCT ATTTTTAGAA AGGGTTTTTA TGGACCAATG CCCCAGTTGT CAGTCAAAGC 120CGTTGGTGTT TTCATTGTTT AAAATGTCAC CTATAAAACG GGCATTATTT ATGTTTTTTT 180TCCCTTTGTT CATATTCTTT TGCATTCCTG ATTATTGTAT GTATCGTGTA AAGGAAGTCT 240GTA 243 (2) INFORMATION FOR SEQ ID NO: 164: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 266 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 164: CCTGGGTCCGTCCTCCAACC CCTCACGCCC AAACCCTCCG ACTTTCACTT CTTGAAGTGA 60 TCGGAAAGGGCAGTTTTGGA AAGGTTCTTC TGGCTAGGCA CAAGGCAGAA GAAGTATTCT 120 ATGCAGTCAAAGTTTTACAG AAGAAGCCAT CCTGAAGAAG AAAGGAAGGA AGCATATTAT 180 GTCAGAGCGGAATGTTCTGT TGAAGAATGT GAAGCACCCT TTCCTGGTGG GCCTTCACTT 240 CTCATTCCAGACCGCTGACA AGCTCT 266 (2) INFORMATION FOR SEQ ID NO: 165: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 204 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 165: GATGCTGAACACAAAAAGAA AGAAGAAAAG GAAGAGGAGG AGCAAGAGAA GCTGAAGGGA 60 GGGAGCCTTGGCGAAAATCA GATCAAAGAT GAGAAGATTA AAAAGGACAA AGAGCCCAAA 120 GAAGAGTCAAGAGCTTCTTG GATAGAAAGA AAGGATTTAC AGAGTGAGGC GCAGAATGGA 180 GATTCATGACCCACAAACTT AAAC 204 (2) INFORMATION FOR SEQ ID NO: 166: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 200 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 166: AAAGCCAATTGGTAGAGAAA TTGAAGACAC AAATGCTGGA TCAGGAAGAG CTTCTGGCAT 60 CAACCAGAAGGGATCAAGAT AATATGCAAG CTGAACTGAA TCGCCTCCAA GCAGAAAATG 120 ATGCTTCTAAAGAAGAGTAA AGAGTTTTAC AGGCCTTAGA GGACTGCTGT TAATTATGAT 180 CAGAGTTCAGGAGTTAAGAC 200 (2) INFORMATION FOR SEQ ID NO: 167: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 337 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 167: CTGCTTGATGTCCTGTGTAG CGAATGTCAC AGCGTACAAC ATTGTTAGTG TAGTCTGATT 60 CAGGCACCAGGTAGCTGGGG TTTACACTGA CCTTTAGAAT GTAGTTTCCA GGTTGTACAT 120 CTGTAATATCAATCCACTGG CAGTCTATGT CTGCCGCATA GGTGTCATAA CATCCAGGAC 180 TCAATCCCTGTGTGTGTGCA GTGCACGCAA AGGCCCTGTG GTACCCATAG TCACAGGACG 240 TGTCCTCCAGACAGAAGCTT GCTTTGTGGC CTTCAGCCAC TCTCCTCTGT GTGTTGGCAT 300 CAACGAGAAGCCGAATTCTC GAGATATCCA TCACACT 337 (2) INFORMATION FOR SEQ ID NO: 168:(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 337 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:168: CTGCTTGATG TCCTGTGTAG CGAATGTCAC AGCGTACAAC ATTGTTAGTG TAGTCTGATT60 CAGGCACCAG GTAGCTGGGG TTTACACTGA CCTTTAGAAT GTAGTTTCCA GGTTGTACAT 120CTGTAATATC AATCCACTGG CAGTCTATGT CTGCCGCATA GGTGTCATAA CATCCAGGAC 180TCAATCCCTG TGTGTGTGCA GTGCACGCAA AGGCCCTGTG GTACCCATAG TCACAGGACG 240TGTCCTCCAG ACAGAAGCTT GCTTTGTGGC CTTCAGCCAC TCTCCTCTGT GTGTTGGCAT 300CAACGAGAAG CCGAATTCTC GAGATATCCA TCACACT 337 (2) INFORMATION FOR SEQ IDNO: 169: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 374 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 169: GATCTGACAC TACAGCATGA GCGTTAGATT TCATAAAATTATTTTTCTTC TAAATGCTGG 60 AAACTCTAAG GGTTTATTCA GAAAAAAAAC TGGCCAATTTTCAAATGGCT TAGAAGCAGG 120 GTTAATTAAG TATTGAATGA GCCACTGTGA TATCCTGATGACACCCAGTC ACAATGACAG 180 TTTTGAAGCA TACAACCAAA ACAATTGAGA TCTCAAAACTATTTTACATC ACTTATGGTA 240 ATGTTATGTA AAAATGAAAA TGCTTTCTGT GGAAGTTACATTCTTTACCA GGTCTTTAAC 300 ATAAATTAAC ACGACGTCGA GTAAGCCTTT GTTCGGAAGACAAACTAGTT TGTGAGTTCA 360 GTCAGATCCC AGCT 374 (2) INFORMATION FOR SEQ IDNO: 170: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 334 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCEDESCRIPTION: SEQ ID NO: 170: AGTTGCCAGG ACCACCACCA TAGTTGCCAG GTTCATCATAAACAAATCCA ACATCAATCT 60 TAAATTCCCC CATCAGACAA TCTGCCCTCA AAGAATGGGAATTATAAACC CGGATACTGA 120 TGATCTCATC CATGAGCTCA GAGGGTGTGA TGTGCACATTGTAGAAAAAT AACTCGTCAA 180 AAAACGGATT GTTCCCTCTC TTGATTCTCG TGCGATGCGTCTGACCACAG ATGTGAACTT 240 TCACCACGGG CCTTATGTTG TTGCCGCATA ACTGACGGCCCTCGATCACT CTGACACGGA 300 TCTGGAAATC TGTGGCTTGT TGGACAGCAT CCTT 334 (2)INFORMATION FOR SEQ ID NO: 171: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 380 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 171: AAGCCGTGTC CCAAAGAATGGATAGAGACG CGATCAGATG CGACAGTGCT GTGGAGAAAG 60 CCCAGGAACC TGCACAATTGCCCTGGTCCA ATGGCTCGTG GATCAGGTTG GGCCACTTCT 120 CTGAAGCTTC AAAGGCAGTGGGTAGCACTT CCCCTTGGCC CAGCACCGTA TAAATCTCAT 180 TCATATTCAT GACAGTGGAGGATGGGCGGA TTGTGCCCAG GCGGTACGGA ATGCCCTCAT 240 CCAGGGTCAT GCCCCAGAAGGCACTGTGGT TCCCAGCCTG CCACCCGTAG TTGCCTCGGT 300 TGATGGCTTT AATCATGTCTGGTCACTAGA CACGGCTTAA GCGAATCTCG AGATATCCAT 360 CACACTGGCG GCGTCGAGAT380 (2) INFORMATION FOR SEQ ID NO: 172: (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 353 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL:NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINALSOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 172: AAGCCGTGTC TGATGATGGAGGTAGTGGTG GGGGAGGAGG GACTGAGGGT CCTGAGGTGG 60 TGGCCCCTGG AACTGATCCCACATAGTTAC CCACTGCTAG TTCTGACCCC GTGGACAACG 120 TGCCAGAGGC CATGACTGGCAGTATGGCAA TGTCCCCATC CCCTTTCTTC TTAATTTTAA 180 TGGTCCCTTG TTTCTCCAGTTCGTGAATCT TTTTTTCCAG GGTAGACTGT CTTTGAATGG 240 CTTCTTCCTT TTCTTTGACCATTTTTCTTA ACGTGTGAAC TTGGGTATTT GCATCTTTGT 300 AGATTTCCGG ACAACATCAGTTCCTTATTC CTCTGCATAA GTTGCTTTCA GTT 353 (2) INFORMATION FOR SEQ ID NO:173: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 350 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:<Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:173: CGAGTCAGAC ACATGAAAGC AAAACGCGGG CAGATAAAAC GATCGCCTTA CCTTCTAGCA60 AAAATCTGAA GCTTGTGTCA GAAACAAAGA CTCAGAAAGG TTTGTTTTCA GATGAAGAAG 120ACTCTGAGGA TTTGTTTTCT TCTCAAAGTT CAAGTAAGCC AAAAAGTGCA TCACTTTCAT 180CCAGCCAGCC CCCAACATCA GTCTCCCTTT TTGGTGATGA AGATGAAGAG GACAGTCTTT 240TTGGGAGTGC AGCAGCTAAG AAGCAGACTT CATCTCTACA ACCTCAGAGT CAAGAGAAAG 300CAAAGCCTTC CGAGCAGCCC TCAAAGAAGA CATCTGCCTT GTTGTTCAGA 350 (2)INFORMATION FOR SEQ ID NO: 174: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 377 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 174: CGAGTCAGAC TTAATTTAAAAACGAAACAA AACAAAAATA ACATAGTTTA GAAATCAAGG 60 AGAAAGGACA GATAGTCTAAGAAAAAAGAC AACACAAAAG AGGGGCAGGG CGGCCAGCTT 120 GCATCAGGGA TCTTGGCTGGAGACCTGCTT TGAATAGGTT TCTTGCAGGT ATTTCTTAAA 180 TGCTGTGGGG TTTTTCCAGAGTTCCGCAGC GTGTGTGTTC AAAGGGCTAT CGATGTTGGG 240 TTCTCCTAGC AGGCTCTGGATAGAGAGCAA GATAGTCCTG ACATCATATA GTGCAGACCA 300 CTTATCCTTG AGGATGTCCGGCAGATGTTG CCTGGGTGTC ACGTTGGGGT GGTAGCAGGG 360 TGTGAGGAAC TTCACTG 377(2) INFORMATION FOR SEQ ID NO: 175: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 326 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 175: CGAGTCAGAC ACTCCTGGCTCCTGGATTCT TTAGATGCCT CCATCAGACT GGGTACTTTA 60 GATGCCTCCA TCAGACTACTTCGTCATTGT ATTTCTCAGT TCGCTCAGGG CAAGCGGCAG 120 TCTCTGGGCT GCTGTGGCAGGTGCCACCAC TGCATTTAAA AGTTAAAATT TCTTCAAATA 180 TTCCCATCAA GGCCTTGTAGCCTCTGAGAT TGGTTTACTA TTTGCCCAGT TATTTAAAGC 240 TCTCTGCATT CCTTCCTGATTTAATATTGC TATGGCCAGG ACAATGTGTA GAAGTAAAAA 300 GGATATCATA TTTACAGGTGTAACGC 326

I claim:
 1. A method for identifying a sequence expressed in ametastasis comprising the steps of: a) transfecting an oncogenicsequence into a mammalian cell to form a population of transfectedcells; b) administering tranfected cells to a primary site of a hostmammal to form a primary tumor; c) maintaining said mammal for a periodof time sufficient to develop a metastasis at a secondary site; d)amplifying expressed RNA sequences of the transfected cells andexpressed RNA sequences of the metastasis by differential-display PCR;and e) comparing the amplified expressed RNA sequences of thetransfected cells with the amplified expressed RNA sequences of themetastasis and identifying the sequence expressed at a higher level inthe metastasis as compared to the expressed RNA sequences of thetransfected cells.
 2. The method of claim 1 wherein the mammalian cellis transfected by calcium phosphate transfection, viral transduction,lipofection, dextran sulfate transfection or electroporation.
 3. Themethod of claim 1 wherein the oncogenic sequence is a sequence of thegene that erodes the oncoproteins p21, p34, p53, myc, ras or src.
 4. Themethod of claim 1 wherein the oncogenic sequence is a sequence thatenhances metastatic potential.
 5. The method of claim 4 wherein theoncogenic sequence is a sequence of the gene that encodes cyclin D1,caveolin or TGF-β1.
 6. The method of claim 1 wherein the mammalian cellis treated with an agent that alters gene expression prior to theadministration of said cell to said host mammal.
 7. The method of claim6 wherein the agent is benzanthracene (BA), dimethyl benzanthracene(DMBA) or 5-azacytidine.
 8. The method of claim 1 wherein the mammaliancell is a primary cell or an established cell line.
 9. The method ofclaim 1 wherein the mammalian cell is isolate from urogenital sinustissue.
 10. The method of claim 1 wherein the mammalian cell is a fetalcell.
 11. The method of claim 1 wherein the mammalian cell contains agene selected from the group consisting of TGF-β1, cyclin D1, p21, p34,p53, ras, and myc.
 12. The method of claim 1 wherein the mammalian cellis isolated from the same species as the host mammal.
 13. The method ofclaim 1 wherein the mammalian cell and the host mammal arehistocompatible.
 14. The method of claim 1 wherein the mammalian celland the host mammal are syngeneic.
 15. The method of claim 1 wherein thetransfected cell is isolated and maintained in vivo or in vitro for aperiod of time prior to introduction of said cell to the host mammal.16. The method of claim 1 wherein the expressed sequences of thetransfected cells are obtained from a cell line of immortalizedtransfected cells.
 17. The method of claim 1 wherein the transfectedcells are administered to the primary site by subcutaneous implantation.18. The method of claim 1 wherein the host mammal is a mouse, a rabbitor a primate.
 19. The method of claim 1 wherein the host mammal is asyngeneic, xenogeneic, immunocompromised or transgenic host mammal. 20.The method of claim 1 further comprising suppressing expression of TGF-αin the host mammal prior to the introduction of transfected cells intosaid host mammal.
 21. The method of claim 1 wherein the primary site isthe renal capsule, the prostate or the testis.
 22. The method of claim 1wherein the secondary site is selected from the group of sitesconsisting of lung, kidney, liver, lymph nodes, brain, bone, testis,spleen, ovaries and mammary.
 23. The method of claim 1 whereindifferential display PCR is performed with an anchor primer and avariable primer.
 24. The method of claim 22 wherein the anchor primercomprises a polythymidine sequence and a dinucleotide sequence connectedto a 3′-terminus.
 25. The method of claim 24 wherein the polythymidinesequence comprises between about 5 to about 30 thymidines.
 26. Themethod of claim 24 wherein the dinucleotide sequence is selected fromthe group of sequences consisting of AA, AG, AC, AT, GA, GG, GC, GT, CA,CG, CC and CT.
 27. The method of claim 23 wherein the anchor primer orthe variable primer comprise a detectable moiety selected from the groupconsisting of radioactive moieties, phosphorescent moieties, magneticmoieties, luminescent moieties and conjugatable moieties.
 28. The methodof claim 23 wherein the anchor primer and the variable primer have acommon sequence.
 29. The method of claim 7 wherein the agent is aretinoid.
 30. A method for identifying a sequence expressed inmetastasis comprising the steps of: a) pretreating a mammalian cell withan agent that enhances metastatic potential to form a population ofcells predisposed to metastasis; b) introducing the pretreated cells toa primary site of a host mammal; c) maintaining said mammal for a periodof time sufficient to develop a metastasis at a secondary site; d)amplifying expressed RNA sequences of pretreated cells and expressed RNAsequences of the metastasis by differential-display PCR; and e)identifyg the sequence expressed at a higher level in the metastasis ascompared to expressed RNA sequences of the pretreated cells.
 31. Themethod of claim 30 further comprising the step of treating cells of theprimary or secondary sites with a genotoxic agent prior toamplification.
 32. The method of claim 31 wherein the genotoxic agent isbenzanthracene (BA), dimethyl benzanthracene (DMBA) or 5-azacytidine.33. The method of claim 30 further comprising the step of comparing theexpressed sequences amplified from the metastasis with expressedsequences amplified from mammalian cells before pretreatment to identifythe sequence selectively expressed in the metastasis.
 34. The method ofclaim 30 wherein the chemical compound is a benzanthracene, dimethylbenzanthracene, or 5-azacytidine.
 35. The method of claim 30 wherein themammalian cell is transfected, prior to the administration of said cellto the host mammal, with an oncogenic sequence before or after treatmentof said cell with the agent that enhances metastatic potential.
 36. Themethod of claim 30 wherein the mammalian cell is a cell line.
 37. Themethod of claim 30 wherein the mammalian cell is isolated from lymphatictissue, hematopoietic cells, reproductive tissues or urogenital sinustissue.
 38. The method of claim 30 wherein the mammalian cell is a fetalcell.
 39. The method of claim 30 wherein the mammalian cell is isolatedfrom a transgenic animal.
 40. The method of claim 30 wherein the primarysite is the renal capsule, the prostate or the testis.
 41. The method ofclaim 30 wherein the secondary site is selected from the group of sitesconsisting of lung, kidney, liver, lymph nodes, brain, bone, testis,spleen, ovaries and mammary.
 42. The method of claim 30 whereindifferential display PCR is performed using an anchor primer and avariable primer.
 43. A method of screening a biological tissue for thepresence of a metastasis comprising contacting the tissue with a nucleicacid probe, wherein the probe detects the presence of a nucleic acidmolecule comprising SEQ ID NO:89 or its complement, and wherein anincreased level of a nucleic acid molecule comprising SEQ ID NO:89 orits complement in the biological tissue relative to the level of anucleic acid molecule comprising SEQ ID NO:89 or its complement in aprimary tumor is indicative of a metastasis.
 44. The method of claim 1,wherein the tissue is lung, kidney, liver, lymph node, brain, testis,bone, spleen, ovary, or mammary tissue.
 45. The method of claim 1,wherein the tissue is renal capsule, testis, prostate, or ovary tissue.46. The method of claim 1, wherein the method comprises in situhybridization of the probe with the tissue.
 47. The method of claim 1,wherein nucleic acids are extracted from the tissue prior to contactwith the probe.
 48. The method of claim 5, wherein the nucleic acids areamplified prior to contact with the probe.
 49. The method of claim 6,wherein the method comprises different display polymerase chainreaction.
 50. The method of claim 1, wherein the primary tumor in aprostate tumor.